

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

# **BMJ Open**

## ASSOCIATION BETWEEN VITAMIN B12 DEFICIENCY AND METFORMIN USE: A CROSS-SECTIONAL STUDY IN A TERTIARY HOSPITAL

Journal:	BMJ Open
Manuscript ID	bmjopen-2025-100672
Article Type:	Original research
Date Submitted by the Author:	14-Feb-2025
Complete List of Authors:	Phan, Hen Huu; Cho Ray Hospital, Department of Endocrinology Nguyen, An; Cho Ray Hospital, Department of Endocrinology Do, Minh Duc; University of Medicine and Pharmacy
Keywords:	Diabetes Mellitus, Type 2, General diabetes < DIABETES & ENDOCRINOLOGY, Drug Therapy





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related ining, Al training, and similar technologies

#### ASSOCIATION BETWEEN VITAMIN B12 DEFICIENCY AND METFORMIN USE: A CROSS-SECTIONAL STUDY IN A TERTIARY HOSPITAL Authors: Hen Huu Phan<sup>1</sup>, An Thuy Thi Nguyen<sup>1</sup>, Minh Duc Do<sup>2</sup> Affiliations: 1. Department of Endocrinology, Cho Ray Hospital, Ho Chi Minh City, Vietnam 2. Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam Correspondence: Do Duc Minh: ducminh@ump.edu.vn Number of words: 2296 Number of tables: 3 Number of figures: 0 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ** Open

Page	3 of 18
1	
2	
3	14
4	17
5	
6	15
7	16
8	16
9	17
10 11	
12	18
13	10
14	19
15	
16	20
17	0.1
18	21
19	22
20	
21 22	• •
22	23
23 24	24
25	
26	25
27	
28	26
29	27
30	27
31	
32	28

ABSTRACT

Background: Vitamin B12 deficiency is a common and neglected adverse effect experienced by type 2 diabetic patients treated with metformin. A lack of vitamin B12 may have severe consequences, such as fatigue, macrocytic anemia, and worsened peripheral diabetic neuropathy. This study aims to identify the rate of vitamin B12 deficiency and the associated factors in type 2 diabetic patients treated with metformin.

- Materials and methods: This cross-sectional study was conducted with 145 type 2 diabetic patients treated with metformin. Levels of vitamin B12 and associated clinical and paraclinical parameters were measured and collected.
- Results: The study population's mean age was 61.5, of which 51.7% were female. The median duration of metformin use was 10 years, and the median metformin dose was 1700 mg. The vitamin B12 deficiency rate was 22.1%. HbA1c, duration of metformin use, and metformin dose were independent factors statistically associated with vitamin B12 deficiency.
- Conclusion: This study identified the rate of vitamin B12 deficiency and associated factors in type 2 diabetic patients treated with metformin. These findings can be helpful in screening patients and replacing vitamin B12 in high risk populations with vitamin B12 deficiency.
- Keywords: metformin; vitamin B12 deficiency; type 2 diabetes mellitus; Vietnam

BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Metformin belongs to the biguanide class and is synthesized from galegine, an isoprenyl derivative of guanidine found in the perennial herb French lilac (*Galega officinalis*)<sup>1</sup>. Metformin is recommended in most treatment guidelines as the first-line drug for the management of type 2 diabetes, based on its effectiveness in blood glucose control, low cost, safety, and cardiovascular benefits, as demonstrated by the UK Prospective Diabetes Study<sup>2,3</sup>.

The drug's effectiveness is dose-dependent, and the mechanism of action of metformin is not fully understood. Extensive evidence obtained in clinical studies and animal models suggests that the main function of metformin in regulating glucose homeostasis is to inhibit hepatic glucose production through the regulation of hepatic gluconeogenesis and glycogenolysis<sup>4,5</sup>. Metformin also improves cellular sensitivity to insulin, thereby enhancing peripheral glucose uptake, mainly in skeletal muscle, and significantly reducing fasting plasma insulin levels<sup>6</sup>. Improvements in insulin sensitivity with metformin may be due to its effects on insulin receptor expression and tyrosine kinase activity. 

The most common adverse effects of metformin are gastrointestinal symptoms, such as diarrhea, nausea, and/or abdominal discomfort<sup>7</sup>. These symptoms are usually mild, transient, and dose-dependent. A rare but more concerning adverse effect of biguanides is lactic acidosis. Risk factors for metformin-induced lactic acidosis include conditions that increase lactate production, such as severe infections, severe liver or kidney disease, recent surgery, and any condition causing hypoxia or decreased tissue perfusion<sup>8,9</sup>.

In 1969, Berchtold et al. first reported vitamin B12 deficiency in patients using metformin, resulting from decreased gastrointestinal vitamin B12 absorption<sup>10</sup>. This effect can occur as early as the third month of using metformin. Several mechanisms have been proposed to explain the effect of metformin, including changes in small intestinal motility leading to overgrowth of intestinal bacteria, competitive inhibition and inactivation of vitamin B12 absorption capacity, alteration of intrinsic factor levels, and interaction with the

61 intracellular cubilin receptor<sup>11,12</sup>. Of these, the most widely accepted mechanism is the 62 inhibition of the calcium-dependent binding of the B12-intrinsic factor complex to the 63 cubilin receptor in the ileum. The HOME study is one of the first clinical trials that 64 confirmed the causative effect of vitamin B12 deficiency by metformin. The results showed 65 that metformin usage at a dose of 850 mg three times daily reduces vitamin B12 levels by 66 19% compared to a placebo<sup>13</sup>.

Type 2 diabetes mellitus is a complicated, heterogeneous, and multifactorial disease of which treatment often requires the combination of metformin and other medications<sup>14–19</sup>, however, there are few studies on vitamin B12 deficiency related to metformin use in Vietnam. In 2023, Huynh et al. conducted a cross-sectional study on the prevalence of vitamin B12 deficiency in type 2 diabetic patients using metformin at the Vinmec Central Park Hospital, a private outpatient clinic in Ho Chi Minh City<sup>20</sup>. Of the 156 type 2 diabetic patients treated with metformin, the rate of vitamin B12 deficiency was 18.6%. Vitamin B12 deficiency may differ depending on region, diet, and studied population; this study set out to investigate the rate of vitamin B12 deficiency and its associated factors in type 2 diabetic patients treated with metformin in Cho Ray Hospital, one of the largest tertiary hospitals in Vietnam.

BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### 

# 79 MATERIALS AND METHODS

### 80 1. Participant recruitment

The protocol for this cross-sectional study was approved by the Ethical Committee of Cho Ray Hospital (approval number 1711/CN-HĐĐĐ). A sample size calculation was performed to estimate the rate of vitamin B12 deficiency in the target population using the formula below:

$$N = Z_{(1-\frac{\alpha}{2})}^2 \frac{p(1-p)}{d^2}$$

In which, Z = 1.96, p = 0.095 (based on a similar study by Ko et al.<sup>21</sup>), and d = 0.05. The estimated patient number was 132. Recruitment took place from March to August 2024. The main inclusion criteria were type 2 diabetic patients treated with metformin for at least 3 months with unchanged dose in the last 3 months. Patients were excluded from the study if they had (i) a recent acute illness, such as severe infection, cancer, or acute coronary syndrome, within the past 3 months, or (ii) serious organ damage defined as cirrhosis, liver cell damage with aspartate aminotransferase or alanine aminotransferase increased  $\geq 3$ times the upper limit of normal, symptoms of heart failure, impaired renal function (serum creatinine levels >1.7 mg/dL for men and >1.5 mg/dL for women), estimated glomerular filtration rate (eGFR)  $\leq$  30 mL/min/1.73 m<sup>2</sup>, or (iii) a history of partial or total gastrectomy or pancreatectomy or colectomy. Patients were also excluded from the study if they were diagnosed with (i) gastrointestinal malabsorption disorders, such as chronic colitis or irritable bowel syndrome, or (ii) pernicious anemia or other hematological disorders. Finally, patients were excluded from the study if they were currently on vitamin B12 or multivitamin replacement, or they had been treated with proton-pump inhibitors or H2-receptor antagonists for at least 12 months consecutively, or they had followed a vegetarian/vegan diet for 3 years.

103 All the selected patients gave their informed written consent upon participating in the 104 study. Baseline characteristics of the patients were recorded (age, gender, weight, height,

Page 7 of 18

#### **BMJ** Open

body mass index (BMI), blood pressure, waist and hip circumference, duration of type 2 diabetes, duration of metformin use, and metformin dose). Hypertension was identified based on the criteria of the American College of Cardiology/American Heart Association Task Force in 2017<sup>22</sup>, or if the patients were currently on antihypertensive drugs. Diabetic peripheral neuropathies were diagnosed based on patient history or the diagnostic criteria of the Toronto Diabetic Neuropathy Expert Group<sup>23</sup>. The metformin usage index (MUI) was calculated by multiplying the daily metformin dose (mg) by usage duration (year) and dividing by 1000<sup>24</sup>.

9 113 2. Paraclinical measurements

Fasting blood samples for all the participants were sent to the central laboratory of the Department of Biochemistry, Cho Ray Hospital. Vitamin B12 and folic acid levels were measured using an Architect i2000SR Immunoassay analyzer (Abbott Laboratories, Chicago, USA). Vitamin B12 deficiency was defined as a vitamin B12 level < 300pg/ml with a normal level of folic acid ( $\geq$  4ng/ml). An ADVIA 1800 Chemistry System (Siemens Healthineers, Erlangen, Germany) was used to measure other biochemical parameters, including fasting plasma glucose, creatinine, AST, ALT, and lipid profile. HbA1c was measured using a G8 HPLC analyzer (Tosoh Corporation, Tokyo, Japan). Total blood count was obtained using a DxH 600 Hematology Analyzer (Beckman Coulter).

123 3. Statistical analysis

Continuous variables were represented either as means  $\pm$  standard deviation (SD) or as medians with interquartile ranges (IQR), depending on their distribution. These variables were compared using either T-tests or Mann-Whitney U tests. Qualitative variables were characterized by frequencies and counts. Chi-square tests were used to compare categorical variables between groups. To investigate the associations between vitamin B12 deficiency and patients' characteristics, univariate and multivariate logistic regression was applied to calculate odds ratios (OR) and 95% confidence intervals (CI). A p-value of equal or less than 0.05 was considered statistically significant in all analyses. Data analysis was 

1 2		
3 4	132	performed using SPSS Statistics for Windows version 20.0 (IBM Corporation, Armonk,
5 6	133	NY, USA)
7 8	134	
9		
10 11		
12 13		
14		
15 16		
17		
18 19		
20 21		
22		
23 24		
25		
26 27		
28 29		
30		
31 32		
33 34		
35		
36 37		
38 39		
40		
41 42		
43		
44 45		
46 47		
48		
49 50		
51		
52 53		
54 55		
56		
57 58		7
59		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
60		i or peer review only interprovention peer only site/about/guidelines.xittiin

#### RESULTS

A total of 145 patients participated in this study. The baseline characteristics of participants are described in Table 1. Briefly, the mean age of the studied population was 61.5, with 51.7% females. The median duration of metformin use was 10 years, the median metformin dose was 1700 mg, and the mean level of HbA1c was 8.1%. The rate of vitamin B12 deficiency was 22.1% (32 out of 145 participants). We could not detect any cases of macrocytic anemia. 

There were no differences between the groups with and without vitamin B12 deficiency in terms of age, gender, BMI, hemoglobin level, MCV, creatinine level, and lipid profile. Patients with vitamin B12 deficiency had significantly longer duration of type 2 diabetes. longer duration of metformin use, higher metformin dose, and lower HbA1c levels than patients without vitamin B12 deficiency. 

Univariate logistic analyses also showed that hypertension, duration of metformin use, metformin dose, HbA1c level, and MUI were statistically associated with vitamin B12 deficiency in the studied population (Table 2). Notably, a duration of metformin use >median (10 years), metformin dose > median dose (1700 mg/day), and MUI  $\geq$  10 were strongly associated with vitamin B12 deficiency with OR (95% CI) = 8.539 (2.459 - 2.459)29.648), 4.942 (1.777–13.749), and 5.095 (1.459–17.788), respectively. After adjusting for covariates using continuous and binomial variable models, HbA1c levels, duration of metformin use, and metformin dose were still independently associated with vitamin B12 deficiency (Table 3). 

BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### 

DISCUSSION

In our study, the vitamin B12 deficiency rate was 22.1% in type 2 diabetic Vietnamese patients treated with metformin for at least 3 months. This deficiency rate may vary between countries and ethnicities, and previous studies have reported a wide range of 4.3% to 30% for patients undergoing metformin treatment<sup>21,25-27</sup>. Our study showed similar results to the study by Kim et al. at Yongin Severance Hospital, South Korea, and Gao et al. at 12 tertiary hospitals in China<sup>28,29</sup>. This similarity may reflect consistency between the studies in average age, duration of type 2 diabetes, duration of metformin use, and metformin dosage. However, our results are higher than those of Ko et al. in South Korea, who found a vitamin B12 deficiency rate of 9.5% with a cut-off of vitamin B12 levels  $\leq$ 300 pg/mL and no folate deficiency (folate > 4 ng/mL)<sup>21</sup>. These differences in vitamin B12 deficiency rates between studies may come from differences in testing methods, patient characteristics, and the duration and dosage of metformin prescribed. Except for similar average ages, our patients' duration of type 2 diabetes, duration of metformin use, and average metformin dosage were all higher than those in Ko's study, which partly explains why the vitamin B12 deficiency rate in our study is higher. More importantly, the subjects in our study had a longer duration of type 2 diabetes, longer duration of metformin use, and a higher prescribed metformin dose compared to the patients in Ko's study<sup>21</sup>. 

Compared with a domestic study in Vietnam by Huynh et al. conducted at Vinmec Central Park Hospital, Ho Chi Minh City in 2023, the vitamin B12 deficiency rate in our study is higher<sup>20</sup>. This difference can be explained by differences in the characteristics of the subjects and the research context. Huvnh's study mainly focused on patients undergoing health checks at a private hospital. These are usually patients with better economic conditions, better access to high quality medical services, and who potentially pay more attention to their diet. Thus, the vitamin B12 deficiency rate in their study is lower. Moreover, the patients in Huynh's study were younger, had lower metformin doses, and a shorter duration of metformin treatment. In contrast, our study was conducted at Cho Ray Hospital, a large tertiary hospital that receives patients with complex and more severe 

medical conditions. Therefore, the patients in our study had a longer disease duration, longer duration of metformin use, higher metformin dose, and a higher rate of vitamin B12 deficiency.

Our study found that metformin dose and duration of metformin use were statistically associated with vitamin B12 deficiency. These findings are similar to previous studies and emphasize again the important role of vitamin B12 screening in patients with long-term use and/or high doses of metformin<sup>28,30</sup>. In addition,  $MUI \ge 10$  was found to be an independent factor that is statistically associated with vitamin B12 deficiency, suggesting that MUI can be used as a reliable and alternative parameter to decide when to screen for vitamin B12 deficiency rather than using duration of metformin use or metformin dose alone. We could not use a cut-off value of 5 years for the duration of metformin use and 5 for MUI because the number of participants with the duration of metformin use of less than 5 years was small (only 21 out of 145 cases), leading to underpowered statistical analyses. Interestingly, lower HbA1c was statistically associated with vitamin B12 deficiency in this study. This outcome may result from the fact that patients achieving lower HbA1c were intensively treated with higher dose of metformin. 

Our study has several limitations. First, we did not measure methylmalonic acid or homocysteine levels; these markers reflect early vitamin B12 deficiency in tissues. Second, data were collected in a single center and may not represent the landscape of type 2 diabetic patients in the southern region of Vietnam. 

In conclusion, our study showed that the rate of vitamin B12 deficiency was up to 22.1% in type 2 diabetic patients with a median of 10 years of metformin use and 1700 mg of metformin dose. This rate presents a warning and requires routine screening and replacement of vitamin B12 in metformin-treated patients. Further multi-center studies are necessary to understand the landscape of vitamin B12 deficiency in patients treated with metformin in Vietnam. 

<ul> <li>6 214 Data availability statement: The data that support the findings of this study are available</li> <li>8 215 within the article text and tables.</li> </ul>	3 4	213	Funding: This study was performed without any specific funding.
215       within the article text and tables.         216       Ethical approval: This study was approved by the Ethics Committee for Medical Researce of Cho Ray Hospital (approval number 1711/CN-HĐĐĐ).         218       Conflict of interest: The authors of this work have nothing to disclose.         219       0         219       0         219       0         219       0         219       0         219       0         219       0         219       0         219       0         219       0         219       0         219       0         219       0         219       0         219       0         210       0         211       0         212       0         213       0         214       0         215       0         216       0         217       0         218       0         219       0         210       0         211       0         211       0		214	Data availability statement: The data that support the findings of this study are available
216       Ethical approval: This study was approved by the Ethics Committee for Medical Researc         217       of Cho Ray Hospital (approval number 1711/CN-HDDD).         218       Conflict of interest: The authors of this work have nothing to disclose.         219       Image: Conflict of interest: The authors of this work have nothing to disclose.         219       Image: Conflict of interest: The authors of this work have nothing to disclose.	8	215	within the article text and tables.
<ul> <li>217 of Cho Ray Hospital (approval number 1711/CN-HDDD).</li> <li>218 Conflict of interest: The authors of this work have nothing to disclose.</li> <li>219</li> <li>219</li> <li>210</li> <li>211</li> <li>211</li> <li>212</li> <li>213</li> <li>214</li> <li>215</li> <li>216</li> <li>217</li> <li>218</li> <li>219</li> <li>2</li></ul>	10	216	Ethical approval: This study was approved by the Ethics Committee for Medical Research
11 Conflict of interest: The authors of this work have nothing to disclose.	12	217	of Cho Ray Hospital (approval number 1711/CN-HĐĐĐ).
44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 59 50 51 52 53 54 55 56 57 58 57 58 59 59 50 51 59 50 51 50 51 52 53 54 55 56 57 58 59 50 50 51 52 53 54 55 56 57 57 58 59 50 57 59 59 50 50 50 50 50 50 50 50 50 50 50 50 50	14	218	Conflict of interest: The authors of this work have nothing to disclose.
57 58 11 59	$\begin{array}{c} 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 23\\ 34\\ 35\\ 36\\ 37\\ 38\\ 90\\ 41\\ 42\\ 44\\ 45\\ 46\\ 47\\ 48\\ 95\\ 51\\ 52\\ 53\\ 55\\ 55\\ \end{array}$	219	
E a visa a visa di su di stata di la stata di la sua di stata da la sut di stata da la sut di stata di stata di	57		11
			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1				
3 4	220	REFERENCES		
4 5				
6	221	1. Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566-1576.		
7 8	222	doi:10.1007/s00125-017-4318-z		
9	223	2. Effect of intensive blood-glucose control with metformin on complications in		
10	223	overweight patients with type 2 diabetes (UKPDS 34). <i>The Lancet</i> .		
11 12	225	1998;352(9131):854-865. doi:10.1016/S0140-6736(98)07037-8		
13				
14 15	226	3. American Diabetes Association Professional Practice Committee. 9. Pharmacologic		
16	227	Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. <i>Diabetes</i>		
17	228	Care. 2024;47(Suppl 1):S158-S178. doi:10.2337/dc24-S009		
18 19	229	4. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and		
20	230	molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122(6):253-		
21 22	231	270. doi:10.1042/CS20110386		
23	232	5. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin.		
24 25	232	<i>Diabetologia</i> . 2017;60(9):1577-1585. doi:10.1007/s00125-017-4342-z		
25	255	Diabelologia. 2017;00(5):1577-1505. doi:10.1007/300125-017-4542-2		
27	234	6. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic		
28 29	235	and cellular mechanisms. <i>Drugs</i> . 1999;58 Suppl 1:31-39; discussion 75-82.		
30	236	doi:10.2165/00003495-199958001-00009		
31 32	237	7. Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. <i>Diabetes</i>		
33	238	Metab. 2011;37(2):90-96. doi:10.1016/j.diabet.2010.11.002		
34 35				
36	239	8. DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis:		
37	240	Current perspectives on causes and risk. <i>Metabolism</i> . 2016;65(2):20-29.		
38 39	241	doi:10.1016/j.metabol.2015.10.014		
40	242	9. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574-579.		
41 42	243	doi:10.1056/NEJM199602293340906		
43	244	10. Berchtold P, Bolli P, Arbenz U, Keiser G. [Disturbance of intestinal absorption		
44 45	244 245	following metformin therapy (observations on the mode of action of biguanides].		
45 46	246	Diabetologia. 1969;5(6):405-412. doi:10.1007/BF00427979		
47	2.0	Diaceterogia: 1909;e(0):100 112: actito:1007/D100127979		
48 49	247	11. Mazokopakis EE, Starakis IK. Recommendations for diagnosis and management		
50	248	of metformin-induced vitamin B12 (Cbl) deficiency. Diabetes Research and Clinical		
51 52	249	Practice. 2012;97(3):359-367. doi:10.1016/j.diabres.2012.06.001		
52 53	250	12. Infante M, Leoni M, Caprio M, Fabbri A. Long-term metformin therapy and		
54	251	vitamin B12 deficiency: An association to bear in mind. <i>World J Diabetes</i> .		
55 56	252	2021;12(7):916-931. doi:10.4239/wjd.v12.i7.916		
57		10		
58 59		12		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		

BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

1

60

1 2 3 4 5 6 7	253 254 255	13. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. <i>BMJ</i> . 2010;340:c2181. doi:10.1136/bmj.c2181
7 8 9 10 11 12 13	256 257 258 259	<ol> <li>Tran NQ, Truong SD, Ma PT, et al. Association of KCNJ11 and ABCC8 single- nucleotide polymorphisms with type 2 diabetes mellitus in a Kinh Vietnamese population. <i>Medicine (Baltimore)</i>. 2022;101(46):e31653. doi:10.1097/MD.00000000031653</li> </ol>
13 14 15 16 17 18 19	260 261 262 263	<ol> <li>Truong S, Tran NQ, Ma PT, et al. Association of ADIPOQ Single-Nucleotide Polymorphisms with the Two Clinical Phenotypes Type 2 Diabetes Mellitus and Metabolic Syndrome in a Kinh Vietnamese Population. <i>Diabetes Metab Syndr Obes</i>. 2022;15:307-319. doi:10.2147/DMSO.S347830</li> </ol>
20 21 22 23	264 265 266	<ol> <li>Mai TP, Luong BA, Ma PT, et al. Genome-wide association and polygenic risk score estimation of type 2 diabetes mellitus in Kinh Vietnamese-A pilot study. <i>J Cell</i> <i>Mol Med.</i> 2024;28(13):e18526. doi:10.1111/jcmm.18526</li> </ol>
24 25 26 27 28	267 268 269	17. Beulens JWJ, Pinho MGM, Abreu TC, et al. Environmental risk factors of type 2 diabetes-an exposome approach. <i>Diabetologia</i> . 2022;65(2):263-274. doi:10.1007/s00125-021-05618-w
29 30 31	270 271	<ol> <li>Prato SD. Rational combination therapy for type 2 diabetes. <i>The Lancet Diabetes</i> &amp; <i>Endocrinology</i>. 2019;7(5):328-329. doi:10.1016/S2213-8587(19)30069-5</li> </ol>
32 33 34 35 36	272 273 274	19. Bailey T. Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm. <i>The American Journal of Medicine</i> . 2013;126(9):S10-S20. doi:10.1016/j.amjmed.2013.06.009
37 38 39 40 41	275 276 277	<ol> <li>Huynh DT, Nguyen NT, Do MD. Vitamin B12 deficiency in diabetic patients treated with metformin: A cross-sectional study. <i>PLoS One</i>. 2024;19(4):e0302500. doi:10.1371/journal.pone.0302500</li> </ol>
42 43 44 45 46	278 279 280	21. Ko SH, Ko SH, Ahn YB, et al. Association of vitamin B12 deficiency and metformin use in patients with type 2 diabetes. <i>J Korean Med Sci.</i> 2014;29(7):965-972. doi:10.3346/jkms.2014.29.7.965
40 47 48 49 50 51 52 53 54 55 56	281 282 283 284 285 286	22. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i> . 2018;71(6):1269-1324. doi:10.1161/HYP.000000000000066
57 58 59		13

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2 3 4 5 6 7	287 288 289	23. Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. <i>Diabetes Care</i> . 2010;33(10):2285-2293. doi:10.2337/dc10-1303
8 9 10 11 12	290 291 292 293	24. Shivaprasad C, Gautham K, Ramdas B, Gopaldatta KS, Nishchitha K. Metformin Usage Index and assessment of vitamin B12 deficiency among metformin and non-metformin users with type 2 diabetes mellitus. <i>Acta Diabetol</i> . 2020;57(9):1073-1080. doi:10.1007/s00592-020-01526-4
13 14 15 16 17	294 295 296	25. Tomkin GH, Hadden DR, Weaver JA, Montgomery DA. Vitamin-B12 status of patients on long-term metformin therapy. <i>Br Med J</i> . 1971;2(5763):685-687. doi:10.1136/bmj.2.5763.685
18 19 20 21 22	297 298 299	<ol> <li>Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP. Association of Biochemical B12 Deficiency With Metformin Therapy and Vitamin B12 Supplements. <i>Diabetes Care</i>. 2012;35(2):327-333. doi:10.2337/dc11-1582</li> </ol>
23 24 25 26 27	300 301 302	<ol> <li>Kos E, Liszek MJ, Emanuele MA, Durazo-Arvizu R, Camacho P. Effect of metformin therapy on vitamin D and vitamin B<sub>12</sub> levels in patients with type 2 diabetes mellitus. <i>Endocr Pract.</i> 2012;18(2):179-184. doi:10.4158/EP11009.OR</li> </ol>
28 29 30 31 32	303 304 305	<ol> <li>Kim J, Ahn CW, Fang S, Lee HS, Park JS. Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. <i>Medicine (Baltimore)</i>. 2019;98(46):e17918. doi:10.1097/MD.00000000017918</li> </ol>
33 34 35 36 37	306 307 308 309	29. Gao L, Ran X, Liu X, et al. The effects of daily dose and treatment duration of metformin on the prevalence of vitamin B12 deficiency and peripheral neuropathy in Chinese patients with type 2 diabetes mellitus: A multicenter cross-sectional study. <i>J Diabetes</i> . 2023;15(9):765-776. doi:10.1111/1753-0407.13428
38 39 40 41 42 43	310 311 312	<ol> <li>Ting RZW, Szeto CC, Chan MHM, Ma KK, Chow KM. Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin. <i>Archives of Internal Medicine</i>. 2006;166(18):1975-1979. doi:10.1001/archinte.166.18.1975</li> </ol>
44 45 46 47 48	313	
49 50 51 52 53		
54 55 56 57 58		14
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Characteristics	Total (N=145)	No vitamin B12	Vitamin B12	p-value
		deficiency (N=113)	deficiency (N=32)	
Age (years)	61.5 ± 11.0	60.6 ± 11.0	64.5 ± 10.7	0.075
Mean $\pm$ SD				
Gender				0.844
Female, N (%)	75 (51.7)	59 (52.5)	16 (50)	
Male, N (%)	70 (48.3)	54 (47.8)	16 (50)	
BMI (kg/m <sup>2</sup> )	22.9 ± 1.9	$22.9 \pm 2.1$	22.8 ± 1.5	0.755
Mean ± SD	4			
Hypertension				0.031
Yes, N (%)	105 (61.9)	77 (68.1)	28 (87.5)	
No, N (%)	40 (38.1)	36 (31.9)	4 (12.5)	
Diabetic peripheral				0.972
neuropathy				
Yes, N (%)	54 (37.2)	42 (37.2)	12 (37.5)	
No, N (%)	91 (62.8)	71 (62.8)	20 (62.5)	
Diabetes duration (years)	10.0 [6.0 - 10.0]	10.0 [5.5 – 15.0]	12.0 [10.0 - 15.0]	0.029
Median [Q1-Q3]				
Metformin use duration	10.0 [6.0 - 10.0]	10.0 [5.5 – 15.0]	12.0 [10.0 - 15.0]	0.044
(years)				
Median [Q1-Q3]		O,		
Metformin dose (mg)	1700.0 [1000.0 -	1700.0 [1000.0 -	1700.0 [1700.0 -	0.001
Median [Q1-Q3]	1850.0]	1700.0]	2000.0]	
Hb (g/dl)	13.6 ± 1.6	13.6 ± 1.6	13.4 ± 1.5	0.674
Mean $\pm$ SD				
MCV (fL)	87.6 ± 6.6	87.1 ± 7.0	89.5 ± 5.1	0.071
Mean $\pm$ SD				
Fasting plasma glucose	158.4 ± 72.1	162.4 ± 77.2	$144.2 \pm 48.2$	0.208
(mg/dl)				
Mean $\pm$ SD				
HbA1c (%)	8.1 ± 1.9	8.3 ± 2.0	7.4 ± 1.6	0.021
Mean $\pm$ SD				
L	1	1	1	1

# Table 1. Baseline characteristics of participants.

2 3		Creatinine (mg/dl)	0.9 [0.7 – 1.0]	0.9 [0.7 – 1.0]	0.9 [0.8 - 1.0]	0.274
4 5		Median [Q1-Q3]				
6 7		Total cholesterol (mmol/l)	146.0 [114.0 -	148.0 [114.5 - 181.5]	138.0 [107.3 –	0.292
8 9		Median [Q1-Q3]	180.0]		164.5]	
9 10		Triglyceride (mmol/l)	163.0 [109.5 -	163.0 [107.0 - 231.0]	162.0 [131.8 -	0.166
11 12		Median [Q1-Q3]	238.0]		307.3]	
13		HDL-C (mmol/l)	44.0 [38.0 - 51.0]	44.0 [39.0 - 52.0]	44.0 [35.0 - 49.0]	0.425
14 15		Median [Q1-Q3]				
16		LDL-C (mmol/l)	75.0 [49.5 - 107.5]	77.0 [53.8 - 112.5]	64.2 [48.2 - 94.9]	0.242
17 18		Median [Q1-Q3]				
19 20		Vitamin B12 level (pg/ml)	478.0 [323.0 -	514.0 [416.0 - 667.5]	233.0 [196.5 -	< 0.001
21		Median [Q1-Q3]	608.0]		273.8]	
22 23		Folate level (µmol/mL)	11.5 ± 3.5	11.6 ± 3.5	11.1 ± 3.5	0.457
24 25		Mean ± SD				
25 26	315	<u> </u>				]

BMI: body mass index, Hb: hemoglobin, MCV: mean cell volume, HDL-C: high-density lipoprotein-cholesterol, LDL-C: low-density lipoprotein-cholesterol. 

BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

	deficiency.		1
	Variables	OR (95% CI)	p-value
	Age	1.034 (0.996 – 1.074)	0.077
	Gender	1.093 (0.498 – 2.396)	0.825
	BMI	0.967 (0.786 – 1.190)	0.753
	Hypertension	3.268 (1.068 - 10.000)	0.038
	Duration of diabetes	1.047 (0.989 – 1.108)	0.115
	Duration of metformin use	1.043 (0.985 – 1.103)	0.147
	Long-term use of metformin	8.539 (2.459 - 29.648)	< 0.001
	(Duration > median duration)		
	Metformin dose	1.002 (1.001 – 1.003)	0.002
	Metformin dose > median dose	4.942 (1.777 – 13.749)	0.002
	Hb	0.949 (0.744 – 1.210)	0.671
	MCV	1.068 (0.993 – 1.148)	0.075
	Fasting plasma glucose	0.995 (0.988 - 1.003)	0.210
	HbA1c	0.733 (0.557 – 0.964)	0.026
	MUI	1.043 (1.009 – 1.078)	0.014
	MUI ≥ 10	5.095 (1.459 – 17.788)	0.011
21	BMI: body mass index, Hb: hemog	globin, MCV: mean cell volume,	MUI: metformin
22	index.		
23			

## **BMJ** Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.	BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I
---	--

324	Table 3. Multivariate logistic regression analysis of factors associated with vitamin B12
325	deficiency.

Long-term use of metformin (Duration > median duration) $10.078 (2.729 - 37.219)$ $0.001$ Metformin dose > median dose $4.429 (1.475 - 13.303)$ $0.008$ Model 3       HbA1c $0.647 (0.480 - 0.874)$ $0.005$ MUI $\ge 10$ $7.644 (2.109 - 27.707)$ $0.002$ MUI: metformin usage index. $7.644 (2.109 - 27.707)$ $0.002$	Duration of metformin use Metformin dose $1.076 (1.005 - 1.151)$ $1.002 (1.001 - 1.004)$ $0.037$ $0.002$ Model 2HbA1c 	Model	Variables	OR (95% CI)	p-value
Metformin dose $1.002 (1.001 - 1.004)$ $0.002$ Model 2HbA1c $0.631 (0.460 - 0.865)$ $0.004$ Long-term use of metformin (Duration > median duration) $10.078 (2.729 - 37.219)$ $0.001$ Metformin dose > median dose $4.429 (1.475 - 13.303)$ $0.008$ Model 3HbA1c $0.647 (0.480 - 0.874)$ $0.005$ MUI $\ge 10$ $7.644 (2.109 - 27.707)$ $0.002$ IUI: metformin usage index.	Metformin dose $1.002 (1.001 - 1.004)$ $0.002$ Model 2HbA1c $0.631 (0.460 - 0.865)$ $0.004$ Long-term use of metformin (Duration > median duration) $10.078 (2.729 - 37.219)$ $0.001$ Metformin dose > median dose $4.429 (1.475 - 13.303)$ $0.008$ Model 3HbA1c $0.647 (0.480 - 0.874)$ $0.005$ MUI $\ge 10$ $7.644 (2.109 - 27.707)$ $0.002$ IUI: metformin usage index.	Model 1	HbA1c	0.624 (0.455 - 0.856)	0.003
Model 2       HbA1c $0.631 (0.460 - 0.865)$ $0.004$ Long-term use of metformin $10.078 (2.729 - 37.219)$ $0.001$ (Duration > median duration)       Metformin dose > median dose $4.429 (1.475 - 13.303)$ $0.008$ Model 3       HbA1c $0.647 (0.480 - 0.874)$ $0.005$ MUI $\ge 10$ $7.644 (2.109 - 27.707)$ $0.002$	Model 2       HbA1c $0.631 (0.460 - 0.865)$ $0.004$ Long-term use of metformin $10.078 (2.729 - 37.219)$ $0.001$ (Duration > median duration)       Metformin dose > median dose $4.429 (1.475 - 13.303)$ $0.008$ Model 3       HbA1c $0.647 (0.480 - 0.874)$ $0.005$ MUI $\ge 10$ $7.644 (2.109 - 27.707)$ $0.002$		Duration of metformin use	1.076 (1.005 – 1.151)	0.037
Long-term use of metformin (Duration > median duration) $10.078 (2.729 - 37.219)$ $0.001$ Metformin dose > median dose $4.429 (1.475 - 13.303)$ $0.008$ Model 3       HbA1c $0.647 (0.480 - 0.874)$ $0.005$ MUI $\ge 10$ $7.644 (2.109 - 27.707)$ $0.002$ MUI: metformin usage index. $7.644 (2.109 - 27.707)$ $0.002$	Long-term use of metformin $10.078 (2.729 - 37.219)$ $0.001$ (Duration > median duration)       Metformin dose > median dose $4.429 (1.475 - 13.303)$ $0.008$ Model 3       HbA1c $0.647 (0.480 - 0.874)$ $0.005$ MUI $\ge 10$ $7.644 (2.109 - 27.707)$ $0.002$ IUI: metformin usage index. $0.002$		Metformin dose	1.002 (1.001 - 1.004)	0.002
(Duration > median duration)       Metformin dose > median dose $4.429 (1.475 - 13.303)$ $0.008$ Model 3       HbA1c $0.647 (0.480 - 0.874)$ $0.005$ MUI $\ge 10$ $7.644 (2.109 - 27.707)$ $0.002$ MUI: metformin usage index.	(Duration > median duration)       Metformin dose > median dose $4.429 (1.475 - 13.303)$ $0.008$ Model 3       HbA1c $0.647 (0.480 - 0.874)$ $0.005$ MUI $\ge 10$ $7.644 (2.109 - 27.707)$ $0.002$ IUI: metformin usage index.	Model 2	HbA1c	0.631 (0.460 - 0.865)	0.004
Metformin dose > median dose $4.429 (1.475 - 13.303)$ $0.008$ Model 3         HbA1c $0.647 (0.480 - 0.874)$ $0.005$ MUI $\geq 10$ $7.644 (2.109 - 27.707)$ $0.002$	Metformin dose > median dose $4.429 (1.475 - 13.303)$ $0.008$ Model 3         HbA1c $0.647 (0.480 - 0.874)$ $0.005$ MUI $\geq 10$ $7.644 (2.109 - 27.707)$ $0.002$		Long-term use of metformin	10.078 (2.729 – 37.219)	0.001
Model 3       HbA1c $0.647 (0.480 - 0.874)$ $0.005$ MUI $\geq 10$ 7.644 (2.109 - 27.707) $0.002$ MUI: metformin usage index. $0.002 (0.002)$ $0.002 (0.002)$	Model 3       HbA1c $0.647 (0.480 - 0.874)$ $0.005$ MUI $\geq 10$ 7.644 (2.109 - 27.707) $0.002$ IUI: metformin usage index.		(Duration > median duration)		
MUI $\ge 10$ 7.644 (2.109 – 27.707) 0.002 IUI: metformin usage index.	MUI $\ge 10$ 7.644 (2.109 – 27.707) 0.002 IUI: metformin usage index.		Metformin dose > median dose	4.429 (1.475 – 13.303)	0.008
fUI: metformin usage index.	fUI: metformin usage index.	Model 3	HbA1c	0.647 (0.480 - 0.874)	0.005
			MUI ≥ 10	7.644 (2.109 – 27.707)	0.002
		IUI: metfor	rmin usage index.		
		IUI: metfoi	rmin usage index.		
		IUI: metfo	rmin usage index.		
		IUI: metfo	rmin usage index.		
		IUI: metfo	rmin usage index.		

MUI: metformin usage index. 

# **BMJ Open**

## ASSOCIATION BETWEEN VITAMIN B12 DEFICIENCY AND METFORMIN USE IN TYPE 2 DIABETIC PATIENTS: A CROSS-SECTIONAL STUDY IN A SOUTH VIETNAM TERTIARY HOSPITAL

Journal:	BMJ Open
Manuscript ID	bmjopen-2025-100672.R1
Article Type:	Original research
Date Submitted by the Author:	14-Apr-2025
Complete List of Authors:	Phan, Hen Huu; Cho Ray Hospital, Department of Endocrinology Nguyen, An; Cho Ray Hospital, Department of Endocrinology Do, Minh Duc; University of Medicine and Pharmacy at Ho Chi Minh City Hospital
<b>Primary Subject Heading</b> :	Diabetes and endocrinology
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	Diabetes Mellitus, Type 2, General diabetes < DIABETES & ENDOCRINOLOGY, Drug Therapy





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



1 2		
- 3 4	1	ASSOCIATION BETWEEN VITAMIN B12 DEFICIENCY AND METFORMIN USE
5 6	2	IN TYPE 2 DIABETIC PATIENTS: A CROSS-SECTIONAL STUDY IN A SOUTH
7 8	3	VIETNAM TERTIARY HOSPITAL
9 10	4	Authors: Hen Huu Phan <sup>1</sup> , An Thuy Thi Nguyen <sup>1</sup> , Minh Duc Do <sup>2</sup>
11 12 13	5	Affiliations:
14 15 16	6	1. Department of Endocrinology, Cho Ray Hospital, Ho Chi Minh City, Vietnam
17	7	2. Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi
18 19 20	8	Minh City, Ho Chi Minh City, Vietnam
21 22	9	Correspondence:
23 24 25	10	Do Duc Minh: <u>ducminh@ump.edu.vn</u>
26 27 28	11	Number of words: 2461
29 30	12	Number of tables: 3
31 32 33	13	Number of tables: 3 Number of figures: 0
34 35	14	
36 37 38		
39 40		
41 42		
43 44		
45 46		
47		
48 49		
50		
51 52		
53		
54 55		
56		
57 58		1
58 59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### BMJ Open

15 ABSTRACT

16 Objectives: Vitamin B12 deficiency is a common and neglected adverse effect experienced 17 by type 2 diabetic patients treated with metformin. A lack of vitamin B12 may have severe 18 consequences, such as fatigue, macrocytic anemia, and worsened peripheral diabetic 19 neuropathy. This study aims to identify the rate of vitamin B12 deficiency and the 20 associated factors in type 2 diabetic patients treated with metformin.

16 21 Design: cross-sectional study.

Setting and participants: This study involved 145 type 2 diabetic patients treated with metformin in Cho Ray hospital, a tertiary healthcare center in the South Vietnam. The levels of vitamin B12 and associated clinical and paraclinical parameters were measured and collected. 

Results: The study population's mean age was 61.5, of which 51.7% were female. The median duration of metformin use was 10 years, and the median metformin dose was 1700 mg. The vitamin B12 deficiency rate was 22.1%. HbA1c, duration of metformin use, and metformin dose were independent factors statistically associated with vitamin B12 deficiency. 

Conclusions: This study identified the rate of vitamin B12 deficiency and associated factors in type 2 diabetic patients treated with metformin. These findings can be helpful in screening patients and replacing vitamin B12 in high risk populations with vitamin B12 deficiency. 

45 35 Keywords: metformin; vitamin B12 deficiency; type 2 diabetes mellitus; Vietnam

47 36 STRENGTHS AND LIMITATIONS OF THIS STUDY:

This study investigated the vitamin B12 deficiency rate and its associated factors in type
 2 diabetic Vietnamese patients treated with metformin, a population with very limited data.

<sup>54</sup> 39 - The levels of methylmalonic acid and homocysteine were not measured in this study,
 <sup>55</sup> 40 these markers reflect early vitamin B12 deficiency in tissues.

- This is a single center, cross-sectional study, therefore, the results may not represent the

prevalence of vitamin B12 deficiency in type 2 diabetic patients treated with metformin in

the southern region of Vietnam.

study, i g in type 2 dia.

BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

data mining, Al training, and similar technologies

Protected by copyright, including for uses related to text and

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### BMJ Open

# 45 INTRODUCTION

Metformin belongs to the biguanide class and is synthesized from galegine, an isoprenyl
derivative of guanidine found in the perennial herb French lilac (*Galega officinalis*)<sup>1</sup>.
Metformin is recommended in most treatment guidelines as the first-line drug for the
management of type 2 diabetes, based on its effectiveness in blood glucose control, low
cost, safety, and cardiovascular benefits, as demonstrated by the UK Prospective Diabetes
Study<sup>2,3</sup>.

The drug's effectiveness is dose-dependent, and the mechanism of action of metformin is not fully understood. Extensive evidence obtained in clinical studies and animal models suggests that the main function of metformin in regulating glucose homeostasis is to inhibit hepatic glucose production through the regulation of hepatic gluconeogenesis and glycogenolysis<sup>4,5</sup>. Metformin also improves cellular sensitivity to insulin, thereby enhancing peripheral glucose uptake, mainly in skeletal muscle, and significantly reducing fasting plasma insulin levels<sup>6</sup>. Improvements in insulin sensitivity with metformin may be due to its effects on insulin receptor expression and tyrosine kinase activity.

The most common adverse effects of metformin are gastrointestinal symptoms, such as diarrhea, nausea, and/or abdominal discomfort<sup>7</sup>. These symptoms are usually mild, transient, and dose-dependent. A rare but more concerning adverse effect of biguanides is lactic acidosis. Risk factors for metformin-induced lactic acidosis include conditions that increase lactate production, such as severe infections, severe liver or kidney disease, recent surgery, and any condition causing hypoxia or decreased tissue perfusion<sup>8,9</sup>.

In 1969, Berchtold et al. first reported vitamin B12 deficiency in patients using metformin, resulting from decreased gastrointestinal vitamin B12 absorption<sup>10</sup>. This effect can occur as early as the third month of using metformin. Several mechanisms have been proposed to explain the effect of metformin, including changes in small intestinal motility leading to overgrowth of intestinal bacteria, competitive inhibition and inactivation of vitamin B12 absorption capacity, alteration of intrinsic factor levels, and interaction with the

intracellular cubilin receptor<sup>11,12</sup>. Of these, the most widely accepted mechanism is the inhibition of the calcium-dependent binding of the B12-intrinsic factor complex to the cubilin receptor in the ileum. The HOME study is one of the first clinical trials that confirmed the causative effect of vitamin B12 deficiency by metformin. The results showed that metformin usage at a dose of 850 mg three times daily reduces vitamin B12 levels by 19% compared to a placebo<sup>13</sup>.

Type 2 diabetes mellitus is a complicated, heterogeneous, and multifactorial disease of which treatment often requires the combination of metformin and other medications<sup>14–19</sup>, however, there are few studies on vitamin B12 deficiency related to metformin use in Vietnam. In 2023, Huynh et al. conducted a cross-sectional study on the prevalence of vitamin B12 deficiency in type 2 diabetic patients using metformin at the Vinmec Central Park Hospital, a private outpatient clinic in Ho Chi Minh City<sup>20</sup>. Of the 156 type 2 diabetic patients treated with metformin, the rate of vitamin B12 deficiency was 18.6%. Vitamin B12 deficiency may differ depending on region, diet, and studied population; this study set out to investigate the rate of vitamin B12 deficiency and its associated factors in type 2 diabetic patients treated with metformin in Cho Ray Hospital, one of the largest tertiary hospitals in Vietnam.

# 90 MATERIALS AND METHODS

### 91 1. Participant recruitment

92 The protocol for this cross-sectional study was approved by the Ethical Committee of Cho 93 Ray Hospital (approval number 1711/CN-HĐĐĐ). A sample size calculation was 94 performed to estimate the rate of vitamin B12 deficiency in the target population using the 95 formula below:

# $N = Z_{(1-\frac{\alpha}{2})}^2 \frac{p(1-p)}{d^2}$

BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

In which, Z = 1.96, p = 0.095 (based on a similar study by Ko et al.<sup>21</sup>), and d = 0.05. The estimated patient number was 132. Recruitment took place from March to August 2024. The main inclusion criteria were type 2 diabetic patients treated with metformin for at least 3 months with unchanged dose in the last 3 months. Patients were excluded from the study if they had (i) a recent acute illness, such as severe infection, cancer, or acute coronary syndrome, within the past 3 months, or (ii) serious organ damage defined as cirrhosis, liver cell damage with aspartate aminotransferase or alanine aminotransferase increased  $\geq 3$ times the upper limit of normal, symptoms of heart failure, impaired renal function (serum creatinine levels >1.7 mg/dL for men and >1.5 mg/dL for women), estimated glomerular filtration rate (eGFR)  $\leq$  30 mL/min/1.73 m<sup>2</sup>, or (iii) a history of partial or total gastrectomy or pancreatectomy or colectomy. Patients were also excluded from the study if they were diagnosed with (i) gastrointestinal malabsorption disorders, such as chronic colitis or irritable bowel syndrome, or (ii) pernicious anemia or other hematological disorders. Finally, patients were excluded from the study if they were currently on vitamin B12 or multivitamin replacement, or they had been treated with proton-pump inhibitors or H2receptor antagonists for at least 12 months consecutively, or they had followed a vegetarian/vegan diet for 3 years.

All the selected patients gave their informed written consent upon participating in the
 study. Baseline characteristics of the patients were recorded (age, gender, weight, height,

body mass index (BMI), blood pressure, waist and hip circumference, duration of type 2 diabetes, duration of metformin use, and metformin dose). Hypertension was identified based on the criteria of the American College of Cardiology/American Heart Association Task Force in 2017<sup>22</sup>, or if the patients were currently on antihypertensive drugs. Diabetic peripheral neuropathies were diagnosed based on patient history or the diagnostic criteria of the Toronto Diabetic Neuropathy Expert Group<sup>23</sup>. The metformin usage index (MUI) was calculated by multiplying the daily metformin dose (mg) by usage duration (year) and dividing by 1000<sup>24</sup>. All the patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research 2. Paraclinical measurements Fasting blood samples for all the participants were sent to the central laboratory of the

Department of Biochemistry, Cho Ray Hospital. Vitamin B12 and folic acid levels were measured using an Architect i2000SR Immunoassay analyzer (Abbott Laboratories, Chicago, USA). Vitamin B12 deficiency was defined as a vitamin B12 level < 300pg/ml with a normal level of folic acid ( $\geq$  4ng/ml). An ADVIA 1800 Chemistry System (Siemens Healthineers, Erlangen, Germany) was used to measure other biochemical parameters, including fasting plasma glucose, creatinine, AST, ALT, and lipid profile. HbA1c was measured using a G8 HPLC analyzer (Tosoh Corporation, Tokyo, Japan). Total blood count was obtained using a DxH 600 Hematology Analyzer (Beckman Coulter). 

<sup>43</sup><sub>44</sub> 136 3. Statistical analysis

Continuous variables were represented either as means  $\pm$  standard deviation (SD) or as medians with interquartile ranges (IQR), depending on their distribution. These variables were compared using either T-tests or Mann-Whitney U tests. Qualitative variables were characterized by frequencies and counts. Chi-square tests were used to compare categorical variables between groups. To investigate the associations between vitamin B12 deficiency and patients' characteristics, univariate and multivariate logistic regression was applied to 

1 2		
3 4	143	calculate odds ratios (OR) and 95% confidence intervals (CI). A p-value of equal
5 6	144	than 0.05 was considered statistically significant in all analyses. Data analysi
7	145	performed using SPSS Statistics for Windows version 20.0 (IBM Corporation, Ar
8 9	146	NY, USA)
10 11	147	
12 13	14/	
14 15		
16		
17 18		
19 20		
21 22		
23 24		
25 26		
27 28		
20 29 30		
31		
32 33		
34 35		
36 37		
38 39		
40 41		
42 43		
44 45		
46		
47 48		
49 50		
51 52		
53 54		
55 56		
57 58		8
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
00		

BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de lesseries in the second s

# 148 RESULTS

A total of 145 patients participated in this study. The baseline characteristics of participants are described in Table 1. Briefly, the mean age of the studied population was 61.5, with 51.7% females. The median duration of metformin use was 10 years, the median metformin dose was 1700 mg, and the mean level of HbA1c was 8.1%. The rate of vitamin B12 deficiency was 22.1% (32 out of 145 participants). We could not detect any cases of macrocytic anemia.

There were no differences between the groups with and without vitamin B12 deficiency in terms of age, gender, BMI, hemoglobin level, MCV, creatinine level, and lipid profile. Patients with vitamin B12 deficiency had significantly longer duration of type 2 diabetes. longer duration of metformin use, higher metformin dose, and lower HbA1c levels than patients without vitamin B12 deficiency. The medications used for type 2 diabetes treatment including insulin, sulfonyl urea, dipeptidyl peptidase 4 inhibitor (DDP4i), and sodium-glucose cotransporter 2 inhibitor (SGLT2i) were not statistically different between the groups with and without vitamin B12 deficiency.

Univariate logistic analyses also showed that hypertension, duration of metformin use, metformin dose, HbA1c level, and MUI were statistically associated with vitamin B12 deficiency in the studied population (Table 2). Notably, a duration of metformin use >median (10 years), metformin dose > median dose (1700 mg/day), and MUI > 10 were strongly associated with vitamin B12 deficiency with OR (95% CI) = 8.539 (2.459 - 2.459)29.648), 4.942 (1.777–13.749), and 5.095 (1.459–17.788), respectively. After adjusting for covariates using continuous and binomial variable models, HbA1c levels, duration of metformin use, and metformin dose were still independently associated with vitamin B12 deficiency (Table 3). 

51 172

174 DISCUSSION
----------------

In our study, the vitamin B12 deficiency rate was 22.1% in type 2 diabetic Vietnamese patients treated with metformin for at least 3 months. This deficiency rate may vary between countries and ethnicities, and previous studies have reported a wide range of 4.3% to 30% for patients undergoing metformin treatment<sup>21,25–27</sup>. Our study showed similar results to the study by Kim et al. at Yongin Severance Hospital, South Korea, and Gao et al. at 12 tertiary hospitals in China<sup>28,29</sup>. This similarity may reflect consistency between the studies in average age, duration of type 2 diabetes, duration of metformin use, and metformin dosage. However, our results are higher than those of Ko et al. in South Korea, who found a vitamin B12 deficiency rate of 9.5% with a cut-off of vitamin B12 levels  $\leq$ 300 pg/mL and no folate deficiency (folate > 4 ng/mL)<sup>21</sup>. These differences in vitamin B12 deficiency rates between studies may come from differences in testing methods, patient characteristics, and the duration and dosage of metformin prescribed. Except for similar average ages, our patients' duration of type 2 diabetes, duration of metformin use, and average metformin dosage were all higher than those in Ko's study, which partly explains why the vitamin B12 deficiency rate in our study is higher. More importantly, the subjects in our study had a longer duration of type 2 diabetes, longer duration of metformin use, and a higher prescribed metformin dose compared to the patients in Ko's study<sup>21</sup>. 

Compared with a domestic study in Vietnam by Huynh et al. conducted at Vinmec Central Park Hospital, Ho Chi Minh City in 2023, the vitamin B12 deficiency rate in our study is higher<sup>20</sup>. This difference can be explained by differences in the characteristics of the subjects and the research context. Huvnh's study mainly focused on patients undergoing health checks at a private hospital. These are usually patients with better economic conditions, better access to high quality medical services, and who potentially pay more attention to their diet. Thus, the vitamin B12 deficiency rate in their study is lower. Moreover, the patients in Huynh's study were younger, had lower metformin doses, and a shorter duration of metformin treatment. In contrast, our study was conducted at Cho Ray Hospital, a large tertiary hospital that receives patients with complex and more severe 

202 medical conditions. Therefore, the patients in our study had a longer disease duration,
203 longer duration of metformin use, higher metformin dose, and a higher rate of vitamin B12
204 deficiency.

Our study found that metformin dose and duration of metformin use were statistically associated with vitamin B12 deficiency. These findings are similar to previous studies and emphasize again the important role of vitamin B12 screening in patients with long-term use and/or high doses of metformin<sup>28,30</sup>. In addition,  $MUI \ge 10$  was found to be an independent factor that is statistically associated with vitamin B12 deficiency, suggesting that MUI can be used as a reliable and alternative parameter to decide when to screen for vitamin B12 deficiency rather than using duration of metformin use or metformin dose alone. We could not use a cut-off value of 5 years for the duration of metformin use and 5 for MUI because the number of participants with the duration of metformin use of less than 5 years was small (only 21 out of 145 cases), leading to underpowered statistical analyses. Interestingly, lower HbA1c was statistically associated with vitamin B12 deficiency in this study. This outcome may result from the fact that patients achieving lower HbA1c were intensively treated with higher dose of metformin. 

Our study has several limitations. First, we did not measure methylmalonic acid or homocysteine levels; these markers reflect early vitamin B12 deficiency in tissues. Second, data were collected in a single center and may not represent the landscape of type 2 diabetic patients in the southern region of Vietnam. 

In conclusion, our study showed that the rate of vitamin B12 deficiency was up to 22.1% in type 2 diabetic patients with a median of 10 years of metformin use and 1700 mg of metformin dose. This rate presents a warning and requires routine screening and replacement of vitamin B12 in metformin-treated patients. Further multi-center studies are necessary to understand the landscape of vitamin B12 deficiency in patients treated with metformin in Vietnam. 

<sup>54</sup> 55 228

1 2		
3 4	229	Author Contributions: HP, AN, MD designed the research study. AN recruited the
5 6	230	participants for the study. HP and MD analyzed the data. HP, AN, and MD wrote the
7 8	231	manuscript. MD is the guarantor.
9 10 11	232	Funding: This study was performed without any specific funding.
12 13	233	Data availability statement: Data supporting the findings of this study are available from
14	234	the corresponding author [MD] on request. Raw data were generated at Cho Ray hospital,
15 16 17	235	Ho Chi Minh City, Vietnam.
18 19	236	Ethical approval: This study was approved by the Ethics Committee for Medical Research
20 21	237	of Cho Ray Hospital (approval number 1711/CN-HĐĐĐ).
22 23 24	238	Conflict of interest: The authors of this work have nothing to disclose.
25 26	239	Patient and public involvement: Patients and/or the public were not involved in the
27 28	240	design, or conduct, or reporting, or dissemination plans of this research.
29 30	241	
31 32		
33 34		
35 36		
37		
38 39		
40 41		
42 43		
44 45		
46		
47 48		
49 50		
51		
52 53		
54 55		
56		
57 58		12
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2 3 4	242	REFERENCES
5 6 7 8	243 244	1. Bailey CJ. Metformin: historical overview. <i>Diabetologia</i> . 2017;60(9):1566-1576. doi:10.1007/s00125-017-4318-z
9 10 11 12 13	245 246 247	<ol> <li>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). <i>The Lancet</i>. 1998;352(9131):854-865. doi:10.1016/S0140-6736(98)07037-8</li> </ol>
14 15 16 17	248 249 250	3. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. <i>Diabetes Care</i> . 2024;47(Suppl 1):S158-S178. doi:10.2337/dc24-S009
18 19 20 21 22	251 252 253	<ol> <li>Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. <i>Clin Sci (Lond)</i>. 2012;122(6):253- 270. doi:10.1042/CS20110386</li> </ol>
23 24 25 26	254 255	<ol> <li>Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. <i>Diabetologia</i>. 2017;60(9):1577-1585. doi:10.1007/s00125-017-4342-z</li> </ol>
27 28 29 30	256 257 258	6. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. <i>Drugs</i> . 1999;58 Suppl 1:31-39; discussion 75-82. doi:10.2165/00003495-199958001-00009
31 32 33 34	259 260	<ol> <li>Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. <i>Diabetes Metab</i>. 2011;37(2):90-96. doi:10.1016/j.diabet.2010.11.002</li> </ol>
35 36 37 38	261 262 263	<ol> <li>DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: Current perspectives on causes and risk. <i>Metabolism</i>. 2016;65(2):20-29. doi:10.1016/j.metabol.2015.10.014</li> </ol>
39 40 41 42	264 265	<ol> <li>Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574-579. doi:10.1056/NEJM199602293340906</li> </ol>
43 44 45 46 47	266 267 268	<ol> <li>Berchtold P, Bolli P, Arbenz U, Keiser G. [Disturbance of intestinal absorption following metformin therapy (observations on the mode of action of biguanides]. <i>Diabetologia</i>. 1969;5(6):405-412. doi:10.1007/BF00427979</li> </ol>
48 49 50 51 52	269 270 271	11. Mazokopakis EE, Starakis IK. Recommendations for diagnosis and management of metformin-induced vitamin B12 (Cbl) deficiency. <i>Diabetes Research and Clinical Practice</i> . 2012;97(3):359-367. doi:10.1016/j.diabres.2012.06.001
53 54 55 56	272 273 274	<ol> <li>Infante M, Leoni M, Caprio M, Fabbri A. Long-term metformin therapy and vitamin B12 deficiency: An association to bear in mind. <i>World J Diabetes</i>. 2021;12(7):916-931. doi:10.4239/wjd.v12.i7.916</li> </ol>
57 58 59		13
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2		
3 4 5 6 7	275 276 277	13. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. <i>BMJ</i> . 2010;340:c2181. doi:10.1136/bmj.c2181
9 10 11 12 13	278 279 280 281	<ol> <li>Tran NQ, Truong SD, Ma PT, et al. Association of KCNJ11 and ABCC8 single- nucleotide polymorphisms with type 2 diabetes mellitus in a Kinh Vietnamese population. <i>Medicine (Baltimore)</i>. 2022;101(46):e31653. doi:10.1097/MD.00000000031653</li> </ol>
13 14 15 16 17 18 19	282 283 284 285	<ol> <li>Truong S, Tran NQ, Ma PT, et al. Association of ADIPOQ Single-Nucleotide Polymorphisms with the Two Clinical Phenotypes Type 2 Diabetes Mellitus and Metabolic Syndrome in a Kinh Vietnamese Population. <i>Diabetes Metab Syndr Obes</i>. 2022;15:307-319. doi:10.2147/DMSO.S347830</li> </ol>
20 21 22 23	286 287 288	<ol> <li>Mai TP, Luong BA, Ma PT, et al. Genome-wide association and polygenic risk score estimation of type 2 diabetes mellitus in Kinh Vietnamese-A pilot study. <i>J Cell</i> <i>Mol Med.</i> 2024;28(13):e18526. doi:10.1111/jcmm.18526</li> </ol>
24 25 26 27 28	289 290 291	17. Beulens JWJ, Pinho MGM, Abreu TC, et al. Environmental risk factors of type 2 diabetes-an exposome approach. <i>Diabetologia</i> . 2022;65(2):263-274. doi:10.1007/s00125-021-05618-w
29 30 31	292 293	18. Prato SD. Rational combination therapy for type 2 diabetes. <i>The Lancet Diabetes &amp; Endocrinology</i> . 2019;7(5):328-329. doi:10.1016/S2213-8587(19)30069-5
32 33 34 35 36	294 295 296	19. Bailey T. Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm. <i>The American Journal of Medicine</i> . 2013;126(9):S10-S20. doi:10.1016/j.amjmed.2013.06.009
37 38 39 40 41	297 298 299	<ol> <li>Huynh DT, Nguyen NT, Do MD. Vitamin B12 deficiency in diabetic patients treated with metformin: A cross-sectional study. <i>PLoS One</i>. 2024;19(4):e0302500. doi:10.1371/journal.pone.0302500</li> </ol>
42 43 44 45 46	300 301 302	21. Ko SH, Ko SH, Ahn YB, et al. Association of vitamin B12 deficiency and metformin use in patients with type 2 diabetes. <i>J Korean Med Sci</i> . 2014;29(7):965-972. doi:10.3346/jkms.2014.29.7.965
46 47 48 49 50 51 52 53 54 55	303 304 305 306 307 308	22. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i> . 2018;71(6):1269-1324. doi:10.1161/HYP.000000000000066
56 57 58		14
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1		
2 3 4 5 6 7	309 310 311	23. Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. <i>Diabetes Care</i> . 2010;33(10):2285-2293. doi:10.2337/dc10-1303
8 9 10 11 12	312 313 314 315	24. Shivaprasad C, Gautham K, Ramdas B, Gopaldatta KS, Nishchitha K. Metformin Usage Index and assessment of vitamin B12 deficiency among metformin and non-metformin users with type 2 diabetes mellitus. <i>Acta Diabetol</i> . 2020;57(9):1073-1080. doi:10.1007/s00592-020-01526-4
13 14 15 16 17	316 317 318	25. Tomkin GH, Hadden DR, Weaver JA, Montgomery DA. Vitamin-B12 status of patients on long-term metformin therapy. <i>Br Med J</i> . 1971;2(5763):685-687. doi:10.1136/bmj.2.5763.685
18 19 20 21 22	319 320 321	<ol> <li>Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP. Association of Biochemical B12 Deficiency With Metformin Therapy and Vitamin B12 Supplements. <i>Diabetes Care</i>. 2012;35(2):327-333. doi:10.2337/dc11-1582</li> </ol>
23 24 25 26 27	322 323 324	<ol> <li>Kos E, Liszek MJ, Emanuele MA, Durazo-Arvizu R, Camacho P. Effect of metformin therapy on vitamin D and vitamin B<sub>12</sub> levels in patients with type 2 diabetes mellitus. <i>Endocr Pract</i>. 2012;18(2):179-184. doi:10.4158/EP11009.OR</li> </ol>
28 29 30 31	325 326 327	<ol> <li>Kim J, Ahn CW, Fang S, Lee HS, Park JS. Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. <i>Medicine (Baltimore)</i>. 2019;98(46):e17918. doi:10.1097/MD.00000000017918</li> </ol>
32 33 34 35 36 37	328 329 330 331	29. Gao L, Ran X, Liu X, et al. The effects of daily dose and treatment duration of metformin on the prevalence of vitamin B12 deficiency and peripheral neuropathy in Chinese patients with type 2 diabetes mellitus: A multicenter cross-sectional study. <i>J Diabetes</i> . 2023;15(9):765-776. doi:10.1111/1753-0407.13428
38 39 40 41 42 43	332 333 334	<ol> <li>Ting RZW, Szeto CC, Chan MHM, Ma KK, Chow KM. Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin. <i>Archives of Internal Medicine</i>. 2006;166(18):1975-1979. doi:10.1001/archinte.166.18.1975</li> </ol>
44 45 46 47	335	
48 49 50 51 52		
53 54 55 56 57		
57 58		15

58 59

1 2 3	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 36 37 37 38 36 37 37 38 37 38 37 38 37 38 37 38 38 38 38 38 38 38 38 38 38	
7 8	
9 10 11	
12 13 14	
15 16 17	
17 18 19	
20 21 22	
23 24 25	
26 27	
20 29 30	
31 32 33	
34 35 36	
37 38 39	
40 41	
42 43 44	
45 46 47	
48 49 50	
51 52	
53 54 55	
56 57 58	
59 60	

# Table 1. Baseline characteristics of participants.

Characteristics	Total (N=145)	No vitamin B12	Vitamin B12	p-value
		deficiency (N=113)	deficiency (N=32)	
Age (years)	61.5 ± 11.0	60.6 ± 11.0	64.5 ± 10.7	0.075
Mean $\pm$ SD				
Gender				0.844
Female, N (%)	75 (51.7)	59 (52.5)	16 (50)	
Male, N (%)	70 (48.3)	54 (47.8)	16 (50)	
BMI (kg/m <sup>2</sup> )	22.9 ± 1.9	$22.9 \pm 2.1$	22.8 ± 1.5	0.755
Mean ± SD				
Hypertension				0.031
Yes, N (%)	105 (61.9)	77 (68.1)	28 (87.5)	
No, N (%)	40 (38.1)	36 (31.9)	4 (12.5)	
Diabetic peripheral				0.972
neuropathy				
Yes, N (%)	54 (37.2)	42 (37.2)	12 (37.5)	
No, N (%)	91 (62.8)	71 (62.8)	20 (62.5)	
Diabetes duration (years)	10.0 [6.0 - 10.0]	10.0 [5.5 – 15.0]	12.0 [10.0 - 15.0]	0.029
Median [Q1-Q3]				
Metformin use duration	10.0 [6.0 - 10.0]	10.0 [5.5 – 15.0]	12.0 [10.0 - 15.0]	0.044
(years)				
Median [Q1-Q3]				
Metformin dose (mg)	1700.0 [1000.0 -	1700.0 [1000.0 -	1700.0 [1700.0 -	0.001
Median [Q1-Q3]	1850.0]	1700.0]	2000.0]	
Hb (g/dl)	13.6 ± 1.6	13.6±1.6	$13.4 \pm 1.5$	0.674
Mean $\pm$ SD				
MCV (fL)	87.6 ± 6.6	87.1 ± 7.0	89.5 ± 5.1	0.071
Mean $\pm$ SD				
Fasting plasma glucose	158.4 ± 72.1	162.4 ± 77.2	$144.2 \pm 48.2$	0.208
(mg/dl)				
Mean $\pm$ SD				
HbA1c (%)	8.1 ± 1.9	8.3 ± 2.0	7.4 ± 1.6	0.021
Mean $\pm$ SD				

Creatinine (mg/dl) Median [Q1-Q3]	0.9 [0.7 – 1.0]	0.9 [0.7 – 1.0]	0.9 [0.8 – 1.0]	0.274
Total cholesterol (mmol/l)	146.0 [114.0 -	148.0 [114.5 – 181.5]	138.0 [107.3 -	0.292
Median [Q1-Q3]	180.0]		164.5]	
Triglyceride (mmol/l)	163.0 [109.5 -	163.0 [107.0 - 231.0]	162.0 [131.8 -	0.166
Median [Q1-Q3]	238.0]		307.3]	
HDL-C (mmol/l)	44.0 [38.0 - 51.0]	44.0 [39.0 - 52.0]	44.0 [35.0 - 49.0]	0.425
Median [Q1-Q3]				
LDL-C (mmol/l)	75.0 [49.5 – 107.5]	77.0 [53.8 – 112.5]	64.2 [48.2 - 94.9]	0.242
Median [Q1-Q3]				
Vitamin B12 level (pg/ml)	478.0 [323.0 -	514.0 [416.0 - 667.5]	233.0 [196.5 -	< 0.00
Median [Q1-Q3]	608.0]		273.8]	
Folate level (µmol/mL)	11.5 ± 3.5	11.6 ± 3.5	11.1 ± 3.5	0.457
Mean $\pm$ SD				
Insulin treatment				0.684
Yes, N (%)	50 (34.5)	38 (33.6)	12 (37.5)	
No, N (%)	95 (65.5)	75 (66.4)	20 (62.5)	
Sulfonyl urea treament		6.		0.370
Yes, N (%)	45 (31.0)	33 (29.2)	12 (37.5)	
No, N (%)	100 (69.0)	80 (70.8)	20 (62.5)	
DPP4i treatment		7		0.089
Yes, N (%)	116 (80.0)	87 (77.0)	29 (90.6)	
No, N (%)	29 (20.0)	26 (23.0)	3 (9.4)	
SGLT2i treatment				0.161
Yes, N (%)	88 (60.7)	72 (63.7)	16 (50.0)	
No, N (%)	57 (39.3)	41 (36.3)	16 (50.0)	

BMI: body mass index, DPP4i: dipeptidyl peptidase 4 inhibitor, Hb: hemoglobin, MCV: mean cell volume, HDL-C: high-density lipoprotein-cholesterol, LDL-C: low-density lipoprotein-cholesterol, SGLT2i: sodium-glucose cotransporter 2 inhibitor. 

60

# BMJ Open

	Variables	OR (95% CI)	p-value
	Age	1.034 (0.996 - 1.074)	0.077
	Gender	1.093 (0.498 – 2.396)	0.825
	BMI	0.967 (0.786 - 1.190)	0.753
	Hypertension	3.268 (1.068 - 10.000)	0.038
	Duration of diabetes	1.047 (0.989 – 1.108)	0.115
	Duration of metformin use	1.043 (0.985 – 1.103)	0.147
	Long-term use of metformin	8.539 (2.459 - 29.648)	< 0.001
	(Duration > median duration)		
	Metformin dose	1.002 (1.001 – 1.003)	0.002
	Metformin dose > median dose	4.942 (1.777 – 13.749)	0.002
	Нb	0.949 (0.744 – 1.210)	0.671
	MCV	1.068 (0.993 – 1.148)	0.075
	Fasting plasma glucose	0.995 (0.988 – 1.003)	0.210
	HbA1c	0.733 (0.557 – 0.964)	0.026
	MUI	1.043 (1.009 – 1.078)	0.014
	$MUI \ge 10$	5.095 (1.459 - 17.788)	0.011
44	BMI: body mass index, Hb: hemog	globin, MCV: mean cell volume,	MUI: metformin
45	index.		
46			

1

Model	Variables	OR (95% CI)	p-value
Model 1	HbA1c	0.624 (0.455 – 0.856)	0.003
	Duration of metformin use	1.076 (1.005 – 1.151)	0.037
	Metformin dose	1.002 (1.001 – 1.004)	0.002
Model 2	HbA1c	0.631 (0.460 - 0.865)	0.004
	Long-term use of metformin	10.078 (2.729 – 37.219)	0.001
	(Duration > median duration)		
	Metformin dose > median dose	4.429 (1.475 - 13.303)	0.008
Model 3	HbA1c	0.647 (0.480 - 0.874)	0.005
	MUI ≥ 10	7.644 (2.109 – 27.707)	0.002

# **BMJ Open**

## ASSOCIATION BETWEEN VITAMIN B12 DEFICIENCY AND METFORMIN USE IN TYPE 2 DIABETIC PATIENTS: A CROSS-SECTIONAL STUDY IN A SOUTH VIETNAM TERTIARY HOSPITAL

Journal:	BMJ Open
Manuscript ID	bmjopen-2025-100672.R2
Article Type:	Original research
Date Submitted by the Author:	30-Apr-2025
Complete List of Authors:	Phan, Hen Huu; Cho Ray Hospital, Department of Endocrinology Nguyen, An; Cho Ray Hospital, Department of Endocrinology Do, Minh Duc; University of Medicine and Pharmacy at Ho Chi Minh City Hospital
<b>Primary Subject Heading</b> :	Diabetes and endocrinology
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	Diabetes Mellitus, Type 2, General diabetes < DIABETES & ENDOCRINOLOGY, Drug Therapy





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



2		
3 4	1	ASSOCIATION BETWEEN VITAMIN B12 DEFICIENCY AND METFORMIN USE
5	2	IN TYPE 2 DIABETIC PATIENTS: A CROSS-SECTIONAL STUDY IN A SOUTH
6 7 8	3	VIETNAM TERTIARY HOSPITAL
9 10	4	Authors: Hen Huu Phan <sup>1</sup> , An Thuy Thi Nguyen <sup>1</sup> , Minh Duc Do <sup>2</sup>
11 12 13	5	Affiliations:
14 15	6	1. Department of Endocrinology, Cho Ray Hospital, Ho Chi Minh City, Vietnam
16 17 18	7	2. Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi
19 20	8	Minh City, Ho Chi Minh City, Vietnam
21 22	9	Correspondence:
23 24 25	10	Do Duc Minh: <u>ducminh@ump.edu.vn</u>
26 27	11	Number of words: 2570
28 29 30	12	Number of tables: 3 Number of figures: 0
31 32	13	Number of figures: 0
33 34 35	14	
36 37		
38 39 40		
41 42		
43 44		
45 46		
47		
48 49		
50		
51		
52 53		
55		
55		
56		
57 58		1
58 59		1
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

15 ABSTRACT

16 Objectives: Vitamin B12 deficiency is a common and neglected adverse effect experienced 17 by type 2 diabetic patients treated with metformin. A lack of vitamin B12 may have severe 18 consequences, such as fatigue, macrocytic anemia, and worsened peripheral diabetic 19 neuropathy. This study aims to identify the rate of vitamin B12 deficiency and the 20 associated factors in type 2 diabetic patients treated with metformin.

16 21 Design: cross-sectional study.

Setting and participants: This study involved 145 type 2 diabetic patients treated with metformin in Cho Ray hospital, a tertiary healthcare center in the South Vietnam. The levels of vitamin B12 and associated clinical and paraclinical parameters were measured and collected. 

Results: The study population's mean age was 61.5, of which 51.7% were female. The median duration of metformin use was 10 years, and the median metformin dose was 1700 mg. The vitamin B12 deficiency rate was 22.1%. HbA1c, duration of metformin use, and metformin dose were independent factors statistically associated with vitamin B12 deficiency. 

Conclusions: This study identified the rate of vitamin B12 deficiency and associated factors in type 2 diabetic patients treated with metformin. These findings can be helpful in screening patients and replacing vitamin B12 in high risk populations with vitamin B12 deficiency. 

45 35 Keywords: metformin; vitamin B12 deficiency; type 2 diabetes mellitus; Vietnam

47 36 STRENGTHS AND LIMITATIONS OF THIS STUDY:

This study investigated the vitamin B12 deficiency rate and its associated factors in type
 2 diabetic Vietnamese patients treated with metformin, a population with very limited data.

<sup>54</sup> 39 - The levels of methylmalonic acid and homocysteine were not measured in this study,
<sup>55</sup> 40 these markers reflect early vitamin B12 deficiency in tissues.

BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

data mining, Al training, and similar technologies

Protected by copyright, including for uses related to text and

- This is a single center, cross-sectional study, therefore, the results may not represent the
prevalence of vitamin B12 deficiency in type 2 diabetic patients treated with metformin in
the southern region of Vietnam.

to beet even only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## 45 INTRODUCTION

Metformin belongs to the biguanide class and is synthesized from galegine, an isoprenyl
derivative of guanidine found in the perennial herb French lilac (*Galega officinalis*)<sup>1</sup>.
Metformin is recommended in most treatment guidelines as the first-line drug for the
management of type 2 diabetes, based on its effectiveness in blood glucose control, low
cost, safety, and cardiovascular benefits, as demonstrated by the UK Prospective Diabetes
Study<sup>2,3</sup>.

The drug's effectiveness is dose-dependent, and the mechanism of action of metformin is not fully understood. Extensive evidence obtained in clinical studies and animal models suggests that the main function of metformin in regulating glucose homeostasis is to inhibit hepatic glucose production through the regulation of hepatic gluconeogenesis and glycogenolysis<sup>4,5</sup>. Metformin also improves cellular sensitivity to insulin, thereby enhancing peripheral glucose uptake, mainly in skeletal muscle, and significantly reducing fasting plasma insulin levels<sup>6</sup>. Improvements in insulin sensitivity with metformin may be due to its effects on insulin receptor expression and tyrosine kinase activity.

The most common adverse effects of metformin are gastrointestinal symptoms, such as diarrhea, nausea, and/or abdominal discomfort<sup>7</sup>. These symptoms are usually mild, transient, and dose-dependent. A rare but more concerning adverse effect of biguanides is lactic acidosis. Risk factors for metformin-induced lactic acidosis include conditions that increase lactate production, such as severe infections, severe liver or kidney disease, recent surgery, and any condition causing hypoxia or decreased tissue perfusion<sup>8,9</sup>.

In 1969, Berchtold et al. first reported vitamin B12 deficiency in patients using metformin, resulting from decreased gastrointestinal vitamin B12 absorption<sup>10</sup>. This effect can occur as early as the third month of using metformin. Several mechanisms have been proposed to explain the effect of metformin, including changes in small intestinal motility leading to overgrowth of intestinal bacteria, competitive inhibition and inactivation of vitamin B12 absorption capacity, alteration of intrinsic factor levels, and interaction with the

intracellular cubilin receptor<sup>11,12</sup>. Of these, the most widely accepted mechanism is the inhibition of the calcium-dependent binding of the B12-intrinsic factor complex to the cubilin receptor in the ileum. The HOME study is one of the first clinical trials that confirmed the causative effect of vitamin B12 deficiency by metformin. The results showed that metformin usage at a dose of 850 mg three times daily reduces vitamin B12 levels by 19% compared to a placebo<sup>13</sup>.

Type 2 diabetes mellitus is a complicated, heterogeneous, and multifactorial disease of which treatment often requires the combination of metformin and other medications<sup>14–19</sup>, however, there are few studies on vitamin B12 deficiency related to metformin use in Vietnam. In 2023, Huynh et al. conducted a cross-sectional study on the prevalence of vitamin B12 deficiency in type 2 diabetic patients using metformin at the Vinmec Central Park Hospital, a private outpatient clinic in Ho Chi Minh City<sup>20</sup>. Of the 156 type 2 diabetic patients treated with metformin, the rate of vitamin B12 deficiency was 18.6%. Vitamin B12 deficiency may differ depending on region, diet, and studied population; this study set out to investigate the rate of vitamin B12 deficiency and its associated factors in type 2 diabetic patients treated with metformin in Cho Ray Hospital, one of the largest tertiary hospitals in Vietnam.

# 90 MATERIALS AND METHODS

## 91 1. Participant recruitment

92 The protocol for this cross-sectional study was approved by the Ethical Committee of Cho 93 Ray Hospital (approval number 1711/CN-HĐĐĐ). A sample size calculation was 94 performed to estimate the rate of vitamin B12 deficiency in the target population using the 95 formula below:

 $N = Z_{(1-\frac{\alpha}{2})}^2 \frac{p(1-p)}{d^2}$ 

BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

In which, Z = 1.96, p = 0.095 (based on a similar study by Ko et al.<sup>21</sup>), and d = 0.05. The estimated patient number was 132. Recruitment took place from March to August 2024. The main inclusion criteria were type 2 diabetic patients treated with metformin for at least 3 months with unchanged dose in the last 3 months. Patients were excluded from the study if they had (i) a recent acute illness, such as severe infection, cancer, or acute coronary syndrome, within the past 3 months, or (ii) serious organ damage defined as cirrhosis, liver cell damage with aspartate aminotransferase or alanine aminotransferase increased  $\geq 3$ times the upper limit of normal, symptoms of heart failure, impaired renal function (serum creatinine levels >1.7 mg/dL for men and >1.5 mg/dL for women), estimated glomerular filtration rate (eGFR)  $\leq$  30 mL/min/1.73 m<sup>2</sup>, or (iii) a history of partial or total gastrectomy or pancreatectomy or colectomy. Patients were also excluded from the study if they were diagnosed with (i) gastrointestinal malabsorption disorders, such as chronic colitis or irritable bowel syndrome, or (ii) pernicious anemia or other hematological disorders. Finally, patients were excluded from the study if they were currently on vitamin B12 or multivitamin replacement, or they had been treated with proton-pump inhibitors or H2receptor antagonists for at least 12 months consecutively, or they had followed a vegetarian/vegan diet for 3 years.

All the selected patients gave their informed written consent upon participating in the
 study. Baseline characteristics of the patients were recorded (age, gender, weight, height,

body mass index (BMI), blood pressure, waist and hip circumference, duration of type 2 diabetes, duration of metformin use, and metformin dose). Hypertension was identified based on the criteria of the American College of Cardiology/American Heart Association Task Force in 2017<sup>22</sup>, or if the patients were currently on antihypertensive drugs. Diabetic peripheral neuropathies were diagnosed based on patient history or the diagnostic criteria of the Toronto Diabetic Neuropathy Expert Group<sup>23</sup>. The metformin usage index (MUI) was calculated by multiplying the daily metformin dose (mg) by usage duration (year) and dividing by 1000<sup>24</sup>. All the patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research 2. Paraclinical measurements

Fasting blood samples for all the participants were sent to the central laboratory of the Department of Biochemistry, Cho Ray Hospital. Vitamin B12 and folic acid levels were measured using an Architect i2000SR Immunoassay analyzer (Abbott Laboratories, Chicago, USA). Vitamin B12 deficiency was defined as a vitamin B12 level < 300pg/ml with a normal level of folic acid ( $\geq$  4ng/ml). An ADVIA 1800 Chemistry System (Siemens Healthineers, Erlangen, Germany) was used to measure other biochemical parameters, including fasting plasma glucose, creatinine, AST, ALT, and lipid profile. HbA1c was measured using a G8 HPLC analyzer (Tosoh Corporation, Tokyo, Japan). Total blood count was obtained using a DxH 600 Hematology Analyzer (Beckman Coulter). 

<sup>43</sup><sub>44</sub> 136 3. Statistical analysis

Continuous variables were represented either as means  $\pm$  standard deviation (SD) or as medians with interquartile ranges (IQR), depending on their distribution. These variables were compared using either T-tests or Mann-Whitney U tests. Qualitative variables were characterized by frequencies and counts. Chi-square tests were used to compare categorical variables between groups. To investigate the associations between vitamin B12 deficiency and patients' characteristics, univariate and multivariate logistic regression was applied to 

# BMJ Open

3 4	143	calculate odds ratios (OR) and 95% confidence intervals (CI). A p-value of equal
5 6	144	than 0.05 was considered statistically significant in all analyses. Data analyse
7	145	performed using SPSS Statistics for Windows version 20.0 (IBM Corporation, An
8 9 10	146	NY, USA)
$\begin{array}{c} 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 9\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 33\\ 34\\ 536\\ 37\\ 38\\ 9\\ 40\\ 41\\ 43\\ 44\\ 56\\ 47\\ 48\\ 9\\ 50\\ 52\\ 53\\ 56\\ 57\\ \end{array}$	147	
58 59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de lesseries in the second s

# 148 RESULTS

A total of 145 patients participated in this study. The baseline characteristics of participants are described in Table 1. Briefly, the mean age of the studied population was 61.5, with 51.7% females. The median duration of metformin use was 10 years, the median metformin dose was 1700 mg, and the mean level of HbA1c was 8.1%. The rate of vitamin B12 deficiency was 22.1% (32 out of 145 participants). We could not detect any cases of macrocytic anemia.

There were no differences between the groups with and without vitamin B12 deficiency in terms of age, gender, BMI, hemoglobin level, MCV, creatinine level, and lipid profile. Patients with vitamin B12 deficiency had significantly longer duration of type 2 diabetes. longer duration of metformin use, higher metformin dose, and lower HbA1c levels than patients without vitamin B12 deficiency. The medications used for type 2 diabetes treatment including insulin, sulfonyl urea, dipeptidyl peptidase 4 inhibitor (DDP4i), and sodium-glucose cotransporter 2 inhibitor (SGLT2i) were not statistically different between the groups with and without vitamin B12 deficiency.

Univariate logistic analyses also showed that hypertension, duration of metformin use, metformin dose, HbA1c level, and MUI were statistically associated with vitamin B12 deficiency in the studied population (Table 2). Notably, a duration of metformin use >median (10 years), metformin dose > median dose (1700 mg/day), and MUI > 10 were strongly associated with vitamin B12 deficiency with OR (95% CI) = 8.539 (2.459 - 2.459)29.648), 4.942 (1.777–13.749), and 5.095 (1.459–17.788), respectively. After adjusting for covariates using continuous and binomial variable models, HbA1c levels, duration of metformin use, and metformin dose were still independently associated with vitamin B12 deficiency (Table 3). 

51 172

54 173

Page 11 of 20

## BMJ Open

# 174 DISCUSSION

In our study, the vitamin B12 deficiency rate was 22.1% in type 2 diabetic Vietnamese patients treated with metformin for at least 3 months. This deficiency rate may vary between countries and ethnicities, and previous studies have reported a wide range of 4.3% to 30% for patients undergoing metformin treatment<sup>21,25–27</sup>. Our study showed similar results to the study by Kim et al. at Yongin Severance Hospital, South Korea, and Gao et al. at 12 tertiary hospitals in China<sup>28,29</sup>. This similarity may reflect consistency between the studies in average age, duration of type 2 diabetes, duration of metformin use, and metformin dosage. However, our results are higher than those of Ko et al. in South Korea, who found a vitamin B12 deficiency rate of 9.5% with a cut-off of vitamin B12 levels  $\leq$ 300 pg/mL and no folate deficiency (folate > 4 ng/mL)<sup>21</sup>. These differences in vitamin B12 deficiency rates between studies may come from differences in testing methods, patient characteristics, and the duration and dosage of metformin prescribed. Except for similar average ages, our patients' duration of type 2 diabetes, duration of metformin use, and average metformin dosage were all higher than those in Ko's study, which partly explains why the vitamin B12 deficiency rate in our study is higher. More importantly, the subjects in our study had a longer duration of type 2 diabetes, longer duration of metformin use, and a higher prescribed metformin dose compared to the patients in Ko's study<sup>21</sup>. There were several reasons why vitamin B12 deficiency rate was 22.1% but did not occur in all the participants. First, not all the participants were treated with metformin for four consecutive years and/or with high metformin dose. Second, the exact mechanisms of vitamin B12 deficiency in patients treated with metformin remained elusive, and who will absolutely develop vitamin B12 deficiency is still an unanswered question. Therefore, current American Diabetes Association guidelines recommend screening for high-risk patients and treating if they have vitamin B12 deficiency rather than treating all patients with metformin use for four consecutive years and more<sup>30</sup>. 

200 Compared with a domestic study in Vietnam by Huynh et al. conducted at Vinmec Central
201 Park Hospital, Ho Chi Minh City in 2023, the vitamin B12 deficiency rate in our study is

higher<sup>20</sup>. This difference can be explained by differences in the characteristics of the subjects and the research context. Huynh's study mainly focused on patients undergoing health checks at a private hospital. These are usually patients with better economic conditions, better access to high quality medical services, and who potentially pay more attention to their diet. Thus, the vitamin B12 deficiency rate in their study is lower. Moreover, the patients in Huynh's study were younger, had lower metformin doses, and a shorter duration of metformin treatment. In contrast, our study was conducted at Cho Ray Hospital, a large tertiary hospital that receives patients with complex and more severe medical conditions. Therefore, the patients in our study had a longer disease duration, longer duration of metformin use, higher metformin dose, and a higher rate of vitamin B12 deficiency. 

Our study found that metformin dose and duration of metformin use were statistically associated with vitamin B12 deficiency. These findings are similar to previous studies and emphasize again the important role of vitamin B12 screening in patients with long-term use and/or high doses of metformin<sup>28,31</sup>. In addition, MUI  $\geq$  10 was found to be an independent factor that is statistically associated with vitamin B12 deficiency, suggesting that MUI can be used as a reliable and alternative parameter to decide when to screen for vitamin B12 deficiency rather than using duration of metformin use or metformin dose alone. We could not use a cut-off value of 5 years for the duration of metformin use and 5 for MUI because the number of participants with the duration of metformin use of less than 5 years was small (only 21 out of 145 cases), leading to underpowered statistical analyses. Interestingly, lower HbA1c was statistically associated with vitamin B12 deficiency in this study. This outcome may result from the fact that patients achieving lower HbA1c were intensively treated with higher dose of metformin. 

Our study has several limitations. First, we did not measure methylmalonic acid or homocysteine levels; these markers reflect early vitamin B12 deficiency in tissues. Second, the sample size was small, and all the data were collected in a single center, therefore, the

## **BMJ** Open

reported results may not represent the landscape of type 2 diabetic patients in the southern region of Vietnam. In conclusion, our study showed that the rate of vitamin B12 deficiency was up to 22.1% in type 2 diabetic patients with a median of 10 years of metformin use and 1700 mg of metformin dose. This rate presents a warning and requires routine screening and replacement of vitamin B12 in metformin-treated patients. Further multi-center studies are necessary to understand the landscape of vitamin B12 deficiency in patients treated with am. metformin in Vietnam. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 

1 2		
2 3 4	238	Author Contributions: HP, AN, MD designed the research study. AN recruited the
5 6	239	participants for the study. HP and MD analyzed the data. HP, AN, and MD wrote the
7 8	240	manuscript. MD is the guarantor.
9 10 11	241	Funding: This study was performed without any specific funding.
12 13	242	Data availability statement: Data supporting the findings of this study are available from
14	243	the corresponding author [MD] on request. Raw data were generated at Cho Ray hospital,
15 16	244	Ho Chi Minh City, Vietnam.
17 18 19	245	Ethical approval: This study was approved by the Ethics Committee for Medical Research
20 21	246	of Cho Ray Hospital (approval number 1711/CN-HĐĐĐ).
22 23 24	247	Conflict of interest: The authors of this work have nothing to disclose.
25 26	248	Patient and public involvement: Patients and/or the public were not involved in the
27 28	249	design, or conduct, or reporting, or dissemination plans of this research.
29 30 31	250	design, or conduct, or reporting, or dissemination plans or this research.
32 33 34 35		
36 37 38		
38 39 40		
41 42		
43 44		
45		
46 47		
48 49		
50		
51 52		
53 54		
55		
56 57		
58 59		13
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2 3 4	251	REFERENCES
5 6 7 8	252 253	1. Bailey CJ. Metformin: historical overview. <i>Diabetologia</i> . 2017;60(9):1566-1576. doi:10.1007/s00125-017-4318-z
9 10 11 12	254 255 256	<ol> <li>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). <i>The Lancet</i>. 1998;352(9131):854-865. doi:10.1016/S0140-6736(98)07037-8</li> </ol>
13 14 15 16 17	257 258 259	3. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. <i>Diabetes Care</i> . 2024;47(Suppl 1):S158-S178. doi:10.2337/dc24-S009
18 19 20 21 22	260 261 262	<ol> <li>Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. <i>Clin Sci (Lond)</i>. 2012;122(6):253- 270. doi:10.1042/CS20110386</li> </ol>
23 24 25 26	263 264	<ol> <li>Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. <i>Diabetologia</i>. 2017;60(9):1577-1585. doi:10.1007/s00125-017-4342-z</li> </ol>
27 28 29 30	265 266 267	6. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. <i>Drugs</i> . 1999;58 Suppl 1:31-39; discussion 75-82. doi:10.2165/00003495-199958001-00009
31 32 33 34	268 269	<ol> <li>Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. <i>Diabetes Metab.</i> 2011;37(2):90-96. doi:10.1016/j.diabet.2010.11.002</li> </ol>
35 36 37 38 39	270 271 272	<ol> <li>DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: Current perspectives on causes and risk. <i>Metabolism</i>. 2016;65(2):20-29. doi:10.1016/j.metabol.2015.10.014</li> </ol>
40 41 42	273 274	<ol> <li>Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574-579. doi:10.1056/NEJM199602293340906</li> </ol>
43 44 45 46 47	275 276 277	<ol> <li>Berchtold P, Bolli P, Arbenz U, Keiser G. [Disturbance of intestinal absorption following metformin therapy (observations on the mode of action of biguanides]. <i>Diabetologia</i>. 1969;5(6):405-412. doi:10.1007/BF00427979</li> </ol>
48 49 50 51	278 279 280	11. Mazokopakis EE, Starakis IK. Recommendations for diagnosis and management of metformin-induced vitamin B12 (Cbl) deficiency. <i>Diabetes Research and Clinical Practice</i> . 2012;97(3):359-367. doi:10.1016/j.diabres.2012.06.001
52 53 54 55 56	281 282 283	12. Infante M, Leoni M, Caprio M, Fabbri A. Long-term metformin therapy and vitamin B12 deficiency: An association to bear in mind. <i>World J Diabetes</i> . 2021;12(7):916-931. doi:10.4239/wjd.v12.i7.916
57 58		14
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

Page 16 of 20

1 2		
3 4 5 6 7	284 285 286	13. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. <i>BMJ</i> . 2010;340:c2181. doi:10.1136/bmj.c2181
8 9 10 11 12	287 288 289 290	<ol> <li>Tran NQ, Truong SD, Ma PT, et al. Association of KCNJ11 and ABCC8 single- nucleotide polymorphisms with type 2 diabetes mellitus in a Kinh Vietnamese population. <i>Medicine (Baltimore)</i>. 2022;101(46):e31653. doi:10.1097/MD.00000000031653</li> </ol>
13 14 15 16 17 18 19	291 292 293 294	15. Truong S, Tran NQ, Ma PT, et al. Association of ADIPOQ Single-Nucleotide Polymorphisms with the Two Clinical Phenotypes Type 2 Diabetes Mellitus and Metabolic Syndrome in a Kinh Vietnamese Population. <i>Diabetes Metab Syndr Obes</i> . 2022;15:307-319. doi:10.2147/DMSO.S347830
20 21 22 23	295 296 297	<ol> <li>Mai TP, Luong BA, Ma PT, et al. Genome-wide association and polygenic risk score estimation of type 2 diabetes mellitus in Kinh Vietnamese-A pilot study. <i>J Cell</i> <i>Mol Med.</i> 2024;28(13):e18526. doi:10.1111/jcmm.18526</li> </ol>
24 25 26 27 28	298 299 300	17. Beulens JWJ, Pinho MGM, Abreu TC, et al. Environmental risk factors of type 2 diabetes-an exposome approach. <i>Diabetologia</i> . 2022;65(2):263-274. doi:10.1007/s00125-021-05618-w
29 30 31	301 302	<ol> <li>Prato SD. Rational combination therapy for type 2 diabetes. <i>The Lancet Diabetes &amp; Endocrinology</i>. 2019;7(5):328-329. doi:10.1016/S2213-8587(19)30069-5</li> </ol>
32 33 34 35 36	303 304 305	19. Bailey T. Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm. <i>The American Journal of Medicine</i> . 2013;126(9):S10-S20. doi:10.1016/j.amjmed.2013.06.009
37 38 39 40 41	306 307 308	<ol> <li>Huynh DT, Nguyen NT, Do MD. Vitamin B12 deficiency in diabetic patients treated with metformin: A cross-sectional study. <i>PLoS One</i>. 2024;19(4):e0302500. doi:10.1371/journal.pone.0302500</li> </ol>
42 43 44 45 46	309 310 311	21. Ko SH, Ko SH, Ahn YB, et al. Association of vitamin B12 deficiency and metformin use in patients with type 2 diabetes. <i>J Korean Med Sci</i> . 2014;29(7):965-972. doi:10.3346/jkms.2014.29.7.965
47 48 49 50 51 52 53 54 55	312 313 314 315 316 317	22. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i> . 2018;71(6):1269-1324. doi:10.1161/HYP.000000000000066
56 57 58		15
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2		
3 4 5 6	318 319 320	23. Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. <i>Diabetes Care</i> . 2010;33(10):2285-2293. doi:10.2337/dc10-1303
7 8 9 10 11 12	321 322 323 324	24. Shivaprasad C, Gautham K, Ramdas B, Gopaldatta KS, Nishchitha K. Metformin Usage Index and assessment of vitamin B12 deficiency among metformin and non-metformin users with type 2 diabetes mellitus. <i>Acta Diabetol</i> . 2020;57(9):1073-1080. doi:10.1007/s00592-020-01526-4
13 14 15 16 17	325 326 327	25. Tomkin GH, Hadden DR, Weaver JA, Montgomery DA. Vitamin-B12 status of patients on long-term metformin therapy. <i>Br Med J</i> . 1971;2(5763):685-687. doi:10.1136/bmj.2.5763.685
18 19 20 21 22	328 329 330	26. Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP. Association of Biochemical B12 Deficiency With Metformin Therapy and Vitamin B12 Supplements. <i>Diabetes Care</i> . 2012;35(2):327-333. doi:10.2337/dc11-1582
23 24 25 26 27	331 332 333	<ol> <li>Kos E, Liszek MJ, Emanuele MA, Durazo-Arvizu R, Camacho P. Effect of metformin therapy on vitamin D and vitamin B<sub>12</sub> levels in patients with type 2 diabetes mellitus. <i>Endocr Pract.</i> 2012;18(2):179-184. doi:10.4158/EP11009.OR</li> </ol>
28 29 30 31	334 335 336	<ol> <li>Kim J, Ahn CW, Fang S, Lee HS, Park JS. Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. <i>Medicine (Baltimore)</i>. 2019;98(46):e17918. doi:10.1097/MD.000000000017918</li> </ol>
32 33 34 35 36 37	337 338 339 340	29. Gao L, Ran X, Liu X, et al. The effects of daily dose and treatment duration of metformin on the prevalence of vitamin B12 deficiency and peripheral neuropathy in Chinese patients with type 2 diabetes mellitus: A multicenter cross-sectional study. <i>J Diabetes</i> . 2023;15(9):765-776. doi:10.1111/1753-0407.13428
38 39 40 41 42	341 342 343	<ol> <li>American Diabetes Association Professional Practice Committee. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes— 2025. <i>Diabetes Care</i>. 2024;48(Supplement_1):S50-S58. doi:10.2337/dc25-S003</li> </ol>
43 44 45 46 47	344 345 346	<ol> <li>Ting RZW, Szeto CC, Chan MHM, Ma KK, Chow KM. Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin. <i>Archives of Internal Medicine</i>. 2006;166(18):1975-1979. doi:10.1001/archinte.166.18.1975</li> </ol>
48 49 50 51 52 53 54 55 56 57	347	
57 58 59		16
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.	BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I
---	--

Characteristics	Total (N=145)	No vitamin B12 deficiency (N=113)	Vitamin B12 deficiency (N=32)	p-valu
Age (years)	61.5 ± 11.0	60.6 ± 11.0	$64.5 \pm 10.7$	0.075
Mean $\pm$ SD				
Gender				0.844
Female, N (%)	75 (51.7)	59 (52.5)	16 (50)	
Male, N (%)	70 (48.3)	54 (47.8)	16 (50)	
BMI (kg/m <sup>2</sup> )	22.9 ± 1.9	$22.9 \pm 2.1$	22.8 ± 1.5	0.755
Mean ± SD				
Hypertension				0.031
Yes, N (%)	105 (61.9)	77 (68.1)	28 (87.5)	
No, N (%)	40 (38.1)	36 (31.9)	4 (12.5)	
Diabetic peripheral				0.972
neuropathy				
Yes, N (%)	54 (37.2)	42 (37.2)	12 (37.5)	
No, N (%)	91 (62.8)	71 (62.8)	20 (62.5)	
Diabetes duration (years)	10.0 [6.0 - 10.0]	10.0 [5.5 – 15.0]	12.0 [10.0 - 15.0]	0.029
Median [Q1-Q3]				
Metformin use duration	10.0 [6.0 - 10.0]	10.0 [5.5 – 15.0]	12.0 [10.0 - 15.0]	0.044
(years)				
Median [Q1-Q3]		O,		
Metformin dose (mg)	1700.0 [1000.0 -	1700.0 [1000.0 -	1700.0 [1700.0 -	0.001
Median [Q1-Q3]	1850.0]	1700.0]	2000.0]	
Hb (g/dl)	13.6 ± 1.6	13.6±1.6	13.4 ± 1.5	0.674
Mean $\pm$ SD				
MCV (fL)	87.6 ± 6.6	87.1 ± 7.0	89.5 ± 5.1	0.071
Mean $\pm$ SD				
Fasting plasma glucose	$158.4 \pm 72.1$	$162.4 \pm 77.2$	$144.2 \pm 48.2$	0.208
(mg/dl)				
Mean ± SD				
HbA1c (%)	8.1 ± 1.9	8.3 ± 2.0	7.4 ± 1.6	0.021
Mean $\pm$ SD				

Creatinine (mg/dl)	0.9 [0.7 – 1.0]	0.9 [0.7 – 1.0]	0.9 [0.8 – 1.0]	0.274
Median [Q1-Q3]				
Total cholesterol (mmol/l)	146.0 [114.0 -	148.0 [114.5 - 181.5]	138.0 [107.3 –	0.292
Median [Q1-Q3]	180.0]		164.5]	
Triglyceride (mmol/l)	163.0 [109.5 -	163.0 [107.0 - 231.0]	162.0 [131.8 -	0.166
Median [Q1-Q3]	238.0]		307.3]	
HDL-C (mmol/l)	44.0 [38.0 - 51.0]	44.0 [39.0 - 52.0]	44.0 [35.0 - 49.0]	0.425
Median [Q1-Q3]				
LDL-C (mmol/l)	75.0 [49.5 - 107.5]	77.0 [53.8 – 112.5]	64.2 [48.2 - 94.9]	0.242
Median [Q1-Q3]				
Vitamin B12 level (pg/ml)	478.0 [323.0 -	514.0 [416.0 - 667.5]	233.0 [196.5 -	< 0.001
Median [Q1-Q3]	608.0]		273.8]	
Folate level (µmol/mL)	11.5 ± 3.5	11.6 ± 3.5	11.1 ± 3.5	0.457
Mean $\pm$ SD				
Insulin treatment				0.684
Yes, N (%)	50 (34.5)	38 (33.6)	12 (37.5)	
No, N (%)	95 (65.5)	75 (66.4)	20 (62.5)	
Sulfonyl urea treament		6.		0.370
Yes, N (%)	45 (31.0)	33 (29.2)	12 (37.5)	
No, N (%)	100 (69.0)	80 (70.8)	20 (62.5)	
DPP4i treatment		2		0.089
Yes, N (%)	116 (80.0)	87 (77.0)	29 (90.6)	
No, N (%)	29 (20.0)	26 (23.0)	3 (9.4)	
SGLT2i treatment				0.161
Yes, N (%)	88 (60.7)	72 (63.7)	16 (50.0)	
No, N (%)	57 (39.3)	41 (36.3)	16 (50.0)	

BMI: body mass index, DPP4i: dipeptidyl peptidase 4 inhibitor, Hb: hemoglobin, MCV: mean cell volume, HDL-C: high-density lipoprotein-cholesterol, LDL-C: low-density lipoprotein-cholesterol, SGLT2i: sodium-glucose cotransporter 2 inhibitor. 

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	Variables	OR (95% CI)	p-value
	Age	1.034 (0.996 - 1.074)	0.077
	Gender	1.093 (0.498 – 2.396)	0.825
	BMI	0.967 (0.786 - 1.190)	0.753
	Hypertension	3.268 (1.068 - 10.000)	0.038
	Duration of diabetes	1.047 (0.989 – 1.108)	0.115
	Duration of metformin use	1.043 (0.985 - 1.103)	0.147
	Long-term use of metformin	8.539 (2.459 - 29.648)	< 0.001
	(Duration > median duration)		
	Metformin dose	1.002 (1.001 – 1.003)	0.002
	Metformin dose > median dose	4.942 (1.777 – 13.749)	0.002
	Hb	0.949 (0.744 – 1.210)	0.671
	MCV	1.068 (0.993 – 1.148)	0.075
	Fasting plasma glucose	0.995 (0.988 - 1.003)	0.210
	HbA1c	0.733 (0.557 – 0.964)	0.026
	MUI	1.043 (1.009 – 1.078)	0.014
	$MUI \ge 10$	5.095 (1.459 - 17.788)	0.011
356	BMI: body mass index, Hb: hemog	globin, MCV: mean cell volume	, MUI: metformin u
357	index.		
358			
		19	
		:p://bmjopen.bmj.com/site/about/guid	

Table 2 Univariate logistic regression analysis of factors associated with vitamin B12 

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.	Enseignement Superieur (ABES) .	BMJ Open: first published as 10.1136/bmjopen-2025-100672 on 14 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique
--	---------------------------------	---

e 21 of 20		ВМЈ Ор	en		
359 360	Table 3. Multivariate logistic regression analysis of factors associated with vitamin B12 deficiency.				
	Model	Variables	OR (95% CI)	p-value	
	Model 1	HbA1c	0.624 (0.455 - 0.856)	0.003	
		Duration of metformin use	1.076 (1.005 – 1.151)	0.037	
		Metformin dose	1.002 (1.001 – 1.004)	0.002	
	Model 2	HbA1c	0.631 (0.460 - 0.865)	0.004	
		Long-term use of metformin	10.078 (2.729 - 37.219)	0.001	
		(Duration > median duration)			
		Metformin dose > median dose	4.429 (1.475 – 13.303)	0.008	
	Model 3	HbA1c	0.647 (0.480 - 0.874)	0.005	
		MUI ≥ 10	7.644 (2.109 – 27.707)	0.002	